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 Heart disease and stroke cause significant death and disability in industrialized 
nations. Oxidized low-density lipoprotein (ox-LDL) is an essential component of the 
plaque formation within arteries that leads to these conditions. Paraoxonase 1 (PON1) is 
an antioxidant enzyme capable of preventing the oxidation of LDL. The purpose of this 
study was to measure the relationship between ox-LDL concentration and PON1 activity 
in response to acute exercise. Fifteen aerobically trained individuals (M=12, F=3, VO2 
max= 54.8 ± 1.7ml⋅kg-1⋅min-1, BMI = 22.9± 0.5kg⋅m-2) completed separate exercise 
treatment sessions at 60% and 80% VO2 max for 30 minutes. Ox-LDL concentration and 
PON1 activity were measured immediately before (PRE), immediately post (0 POST), 
and 15 minutes post (15 POST) exercise. To ascertain the degree of oxidative stress 
induced by the exercise sessions, protein carbonyl (PC) concentration and total 
antioxidant capacity (TAC) were measured at PRE and 0 POST. Repeated measures 
analyses of variance revealed that ox-LDL concentration and PON1 activity failed to 
change significantly in response to both the 60% and 80% treatment sessions. In addition, 
Pearson product moment correlations found no significant relationships between the 
changes in ox-LDL and PON1 at any time point (p>0.05). There were no significant 
changes in PC or TAC from PRE to 0 POST in either treatment. The results from this 
study indicate that thirty minutes of running at 80% VO2max was not sufficient to induce 
oxidative stress and elevate ox-LDL concentrations and PON1 activity in these highly 
trained subjects.  
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CHAPTER I 
INTRODUCTION 
 
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the 
industrialized world. Heart disease and stroke are major forms of CVD and are the first 
and third causes of death in the United States, respectively (Xu, Kochanek, Murphy, & 
Tejada-Vera, 2010). Atherosclerosis, the underlying cause of most heart attacks and 
strokes, is characterized by the development of arterial plaque. The development of 
atherosclerosis involves several complex processes, including the infiltration and 
oxidation of low-density lipoprotein (LDL) within the arterial wall. Oxidized LDL (ox-
LDL) has been shown to be a major contributor to the dangerous accumulation of lipids 
beneath the vascular endothelium. Within the intima the ox-LDL particles can be 
engulfed by macrophages, which in turn comprise the core of arterial plaque.  
In contrast, the human body has the capacity to protect itself from the harmful 
effects of ox-LDL through a variety of mechanisms. In particular, antioxidants in the 
form of enzymes, vitamins, and other reducing agents have the capacity to disrupt 
oxidation processes, and thus prevent LDL oxidation. The balance between pro-oxidants 
and antioxidants plays a key role in the oxidative modification of LDL. Paraoxonase 1 
(PON1) is a circulating antioxidant enzyme that is bound to the surface of high-density 
lipoprotein (HDL). PON1 activity has been shown to have a significant inverse 
 
2 
  
relationship with several oxidative stress-related diseases such as type II diabetes (B. 
Mackness, et al., 1998), metabolic syndrome (Senti, et al., 2003), and coronary artery 
disease (B. Mackness, et al., 2003). In addition, PON1 has been reported to prevent the 
oxidation of LDL in vitro (Camps, Marsillach, & Joven, 2009).Therefore, the action of 
this enzyme has significant implications in the attenuation of oxidative stress and the 
prevention of CVD. It is important to understand how the antioxidant system functions to 
attenuate the oxidation of LDL. However, the in vivo dynamic between ox-LDL and 
PON1 is poorly understood.   
Increased oxygen consumption during physical exercise contributes to elevated 
reactive oxygen species (ROS) generation. The increased ROS concentration can then 
lead to elevated ox-LDL concentration within the circulation. Although exercise training 
may reduce circulating ox-LDL, an isolated bout of exercise can transiently increase ox-
LDL concentration, with values returning to baseline within hours (Tomas, et al., 2002).  
This feature of exercise provides an opportunity to examine the paired response of ox-
LDL concentration and PON1 activity during this time of disrupted ox-LDL homeostasis. 
To date, the explicit measurement of the relationship between ox-LDL and PON1 
following physical activity has not been studied. An examination of this kind should shed 
new light on the in vivo link between these two substances. In addition, it has been 
observed that the intensity of exercise can affect oxidative stress, but this phenomenon 
has not been studied with ox-LDL or PON1. More information about the relationship 
between ox-LDL and PON1 can be gathered by examining these substances after exercise 
bouts of different intensities.   
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Purpose of the Study 
The purpose of this investigation was to examine the association between ox-LDL 
concentration and PON1 activity in response to acute exercise. Additionally, this study 
was designed to measure the influence of oxidative stress, as induced through differing 
exercise intensities, on ox-LDL concentration and PON1 activity. 
 
Specific Aims 
Specific aim #1: Investigate the effect of acute exercise on ox-LDL concentration in 
response to two acute exercise treatments of different intensities. 
Hypothesis 1: Ox-LDL concentration will increase in response to acute exercise to a 
greater extent with the higher exercise intensity. 
Specific aim #2: Investigate the effect of acute exercise on PON1 activity in response to 
two acute exercise treatments of different intensities. 
Hypothesis 2: PON1 activity will increase in response to acute exercise to a greater 
extent with the higher exercise intensity.  
Specific aim #3: Examine the relationship between changes in ox-LDL concentration 
and PON1 activity in response to two acute exercise treatments of different intensities. 
Hypothesis 3a: A significant correlation will exist between exercise-induced changes in 
ox-LDL concentration and PON1 activity in response to the relatively low exercise 
treatment. 
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Hypothesis 3b: A significant correlation will exist between exercise-induced changes in 
ox-LDL concentration and PON1 activity in response to the relatively high exercise 
treatment. 
 
Significance of the Study 
Ox-LDL and PON1 represent two opposing substances in the progression of 
atherosclerosis. Although research related to PON1has increased over the past two 
decades, the role of PON1 in the human body has not been fully described. By measuring 
the changes of PON1 activity in response to exercise, an oxidative stress stimulant, new 
information concerning the utility of PON1 can be obtained. One of the possible 
functions of PON1 is to act as a primary antioxidant upon the rapid increase of ox-LDL. 
It is plausible that the activity of PON1 is up-regulated in conjunction with a rise in 
circulating ox-LDL; however this relationship has not been investigated. This study was 
significant because it was the first attempt to quantify the activity of PON1 in relation to 
the amount of ox-LDL following physical activity, shedding new light onto the possible 
role of PON1 in vivo. The relationship between PON1 and ox-LDL was further defined 
through the use of differing exercise intensity treatments, with each treatment 
hypothesized to produce different levels of oxidative stress, ox-LDL, and PON1.   
 
Limitations 
1. Participants volunteered for this investigation, thus, a random sample was not taken.  
2. Dietary intake was not directly controlled.   
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3. The measurement of ox-LDL and PON1 was taken from the blood; however the 
relationship between these two substances may not be the same in the circulation as it 
is in the arterial intima. 
Delimitations 
1. Participants completed three day dietary intake logs prior to each experimental 
treatment. Participants fasted for 12 hours before each exercise treatment to control 
for dietary influences on blood lipid concentrations.  
2. Participants completed one-week physical activity recall questionnaires prior to each 
experimental treatment.  
3. To prevent possible carry-over effects, participants were instructed not to exercise for 
48 hours prior to each exercise treatment.  
4. Participants were asked otherwise to exercise normally between exercise treatments 
to prevent a detraining effect. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
 
Introduction 
 
Lipoproteins are the primary carriers of lipids in the blood. The shape and 
solubility of lipoproteins confer the properties that allow them to transport insoluble 
lipids within the water-based blood pool. These spherical, insoluble molecules are 
surrounded by a coating of proteins and phospholipids that are amphipathic; that is, they 
have both hydrophobic and hydrophilic regions. The hydrophilic region faces outward 
while the hydrophobic region faces inward. The core of these particles contains primarily 
cholesterol ester and triglyceride. The outer phospholipid-monolayer is diffusible in the 
blood and allows the delivery of cholesterol and triglycerides to the various regions of the 
body. The proteins embedded within the phospholipid monolayer (apolipoproteins) 
confer specificity to the lipoprotein complex, allowing them to be recognized by specific 
receptors on cell surfaces. Apolipoproteins also stimulate certain enzymatic reactions, 
which in turn regulates the lipoproteins’ metabolic function. The cholesterol, triglyceride, 
free fatty acid, protein, and phospholipid composition of lipoproteins varies widely, but 
the general structure is consistent. There are five types of lipoproteins which are typically 
classified by their density. In order of increasing density, the five types are chylomicrons,
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very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low 
density lipoproteins (LDL), and high density lipoproteins (HDL).   
 
Cholesterol Transport 
After ingestion of food, triglycerides (TG), cholesterol, and phospholipids 
undergo digestion primarily in the small intestine through the action of bile salts and 
pancreatic lipase. Digestion hydrolyzes TG into free fatty acids, monoglycerides, and 
glycerol. The lipids are aggregated into particles called micelles.  Micelles’ very small 
diameter allows them access into the intestinal wall and into epithelial cells. In the 
endoplasmic reticulum of the epithelial cell, TG are reconstituted and, along with 
absorbed cholesterol and phospholipid, encased into globules with an apolipoprotein B-
48 and phospholipid coating. These particles, called chylomicrons, are released from the 
epithelial cells into the lymphatic circulation (Hussain, Fatma, Pan, & Iqbal, 2005).  
Chylomicrons eventually enter the great veins in the neck through the thoracic duct. Once 
in the circulation, HDL transfers apo E to the surface of chylomicrons.   
Chylomicrons are the primary carriers of exogenous lipids, with their lipid 
composition being mostly TG. The fate of these lipoproteins can follow one of two 
pathways. One mechanism for chylomicron removal is via lipoprotein lipase (LPL) 
activity. LPL is an enzyme found in most tissues in the body, but primarily in the 
capillary endothelium of adipose, cardiac, and skeletal muscle tissue (Zechner, 1997). As 
chylomicrons pass through the capillaries of these tissues, LPL catalyzes the hydrolysis 
and removal of TG from chylomicrons. The free fatty acids and diacylglycerols are 
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quickly taken up by the tissue cells. The loss of TG from chylomicrons increases its 
density and results in the formation of chylomicron remnants (Hultin & Olivecrona, 
1998). The liver cells express receptors for apoE, enabling them to recognize and 
metabolize chylomicron remnants as they pass through the hepatic circulation. Another 
mechanism for chylomicron removal is directly through the liver (Redgrave, 2004).  
Some chylomicron particles travel through the circulation unaffected by LPL. In this 
case, they are metabolized directly by hepatic cells. The liver is highly capable of using 
lipid from chylomicrons and chylomicron remnants to produce other lipoproteins, energy, 
or bile salts. The lipid portion is hydrolyzed in the hepatocyte to free fatty acids, glycerol, 
monoacylglycerols, diacylglycerols, and cholesterol, but resynthesis of these compounds 
occurs in a manner similar to the events in the intestinal epithelial cell. Fatty acids 
entering the hepatocyte can also be used as a substrate for ATP production. The 
cholesterol portion of lipid delivered to the liver can either be converted to bile salts and 
secreted in the bile or incorporated into VLDL or HDL and released into the plasma.   
The liver can resynthesize TG and, in combination with phospholipid, cholesterol, 
and protein, form VLDL and HDL. VLDL’s primary lipid constituent is TG (its primary 
apolipoprotein is apoB-100), therefore its primary role is to deliver endogenous TG to 
peripheral tissues (Shelness & Sellers, 2001). LPL on the capillary endothelium acts on 
VLDL just as it does on chylomicrons; TG is hydrolyzed and removed from VLDL and 
entered into the surrounding cells. The catabolism of VLDL results in the transient 
formation of IDL. IDL is quickly catabolized via LPL and hepatic lipase (HL) and gives 
rise to the less-buoyant LDL (Havel, 1984).   
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LDL’s primary component is esterified cholesterol. Therefore, its function is to 
transport cholesterol to various tissues throughout the body. The systemic tissues utilize 
cholesterol for membrane formation and sex hormone construction. LDL interacts with 
LDL receptors on cells via its apoB-100, an event that culminates in the removal of the 
lipoprotein from the circulation (Schneider, 1991). Upon interaction between apoB-100 
and the LDL receptor, the lipoprotein is internalized via endocytosis. The number of 
receptors synthesized by cells varies according to cholesterol requirements.  
Opposing the cholesterol delivery role of LDL is the HDL fraction of serum 
lipoproteins. HDL is the smallest of the lipoprotein particles. They are the densest 
because of their high proportion of protein. An important function of HDL is to collect 
unesterified cholesterol from peripheral cells, including lipid-laden macrophages, and 
other lipoproteins where it may have accumulated and return the lipid to the liver for 
excretion in the bile. This phenomenon is called reverse cholesterol transport and is 
traditionally believed to be the main explanation as to why HDL is cardioprotective.  
The formation of HDL is initiated by the secretion of its main apolipoprotein, 
apoA-1. Approximately 2/3 of the apoA-1 is synthesized and released from the liver 
while the intestine is responsible for about 1/3 (Rye & Barter, 2004). Adenosine 
triphosphate binding cassette transporter A-1 (ABCA-1) is a ubiquitously expressed 
cellular lipid transport protein that promotes efflux of phospholipid and free cholesterol 
from cells to lipid-poor apoA-1. ABCA-1 can be found on the surface of the liver, 
intestines, macrophages, and a variety of peripheral tissues (N. Wang & Tall, 2003). The 
lipidation of lipid-poor apoA-1 via ABCA-1 results in the formation of nascent, or pre β, 
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HDL, however this HDL is discoidal and the lipid accounts for only a small percentage of 
its mass. Additional cholesterol is sequestered through the activity of the enzyme lecithin: 
cholesterol acyltransferase (LCAT). LCAT is a plasma enzyme that associates with HDL 
and, through the catalytic activity of apoA-1, esterifies free cholesterol from the plasma 
membrane of other cells and the surface of other lipoproteins (Sviridov, Hoang, Sawyer, 
& Fidge, 2000). The esterification of free cholesterol makes it more hydrophobic and 
draws it to the core of the nascent HDL making it a more spherical, mature HDL particle.   
HDL delivers its cholesterol mostly to the liver by direct and indirect pathways 
(Groen, Oude Elferink, Verkade, & Kuipers, 2004). The direct HDL removal pathways 
involve HDL receptors such as scavenger receptor BI (SR-BI), which mediate the 
selective uptake of cholesterol from HDL. The indirect pathway is mediated by 
cholesteryl ester transfer protein (CETP). This protein exchanges TG from apoB 
containing particles (VLDL, chylomicrons, LDL) for the cholesteryl esters of HDL. 
Chylomicrons deliver cholesterol back to the liver and VLDL is then processed to LDL 
which can be removed from the circulation by the LDL receptors in the liver.TG is not 
stable in HDL, but is degraded by HL so that finally small HDL particles are left which 
restart the uptake of cholesterol from cells. 
The net effect of these properties of HDL is the retrieval of cholesterol from 
peripheral cells and other lipoproteins and its return, as cholesteryl ester, to the liver 
where it can be catabolized and excreted in bile. Reverse cholesterol transport benefits 
the cardiovascular system by reducing the amount of deposited cholesterol in the vascular 
endothelium, thus reducing the risk of fatty plaque formation and atherosclerosis.  This 
 
11 
delivery of cholesteryl ester to the liver presumably explains the correlation of high HDL 
levels with reduced risk of CVD (M. Wang & Briggs, 2004).  
 
Oxidized Low Density Lipoprotein 
Ox-LDL and atherosclerosis. 
Atherosclerosis is a form of arteriosclerosis in which the thickening and 
hardening of the blood vessel is caused by the accumulation of lipid-laden macrophages 
within the arterial wall. Through this process artery walls become narrow and stiff, 
resulting in reduced blood perfusion. Ischemia caused by atherosclerosis is the principal 
cause of angina pectoris, myocardial infarction and ischemic stroke. Given that 
myocardial infarction and ischemic stroke are major forms of heart disease and stroke, 
atherosclerosis clearly presents a major health problem not only in the United States, but 
throughout the world (World Health Organization, 2008).  
The initiation and progression of atherosclerosis consist of very complex 
processes that involve several biological phenomena, such as inflammation, oxidative 
stress, and metabolic disorders. At the center of this pathological development is ox-LDL 
(Stocker & Keaney, 2004). The oxidative modification of LDL has been implicated in a 
number of atherogenic steps in the arterial wall including endothelial dysfunction, 
macrophage migration, smooth muscle cell proliferation, and the release of inflammatory 
cytokines. 
The vascular endothelium, a single layer of cells which lines the inner surface of 
blood vessels, is vital to the health and function of the circulatory system. The genesis of 
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atherosclerosis is initiated by an injury to the endothelium of the artery wall. Once 
endothelial cells become damaged, they can be rendered dysfunctional and unable to 
release normal amounts of vasodilating and antithrombotic cytokines (Davignon & Ganz, 
2004). Potential sources of endothelial insult include hypertension, shear stress, 
dyslipidemia, smoking, diabetes, and ox-LDL (Pennathur & Heinecke, 2007; Ross, 
1993). The altered homeostasis of the endothelium initiates the release of inflammatory 
cytokines, reactive oxygen species (ROS), and prothrombolitic agents (Libby, 2002; 
Ross, 1999). The injury also increases endothelial permeability and adhesiveness to 
monocytes. LDL particles, particularly small, dense LDL, can penetrate into the intima of 
the artery wall through the site of endothelial injury. If the LDL is not already oxidized in 
the circulation, it can become oxidized within the intima due to the ROS released from 
the injured cells and monocyte-derived macrophages (Cathcart, 2004; Harrison, 
Griendling, Landmesser, Hornig, & Drexler, 2003). The oxidation of LDL is an 
important step in atherogenesis. The modified LDL particle contains several bioactive 
lipids capable of exacerbating inflammation and smooth muscle cell migration(Navab, 
Hama, Anantharamaiah, et al., 2000). In particular, blood macrophage recruitment and 
infiltration is enhanced (Kita, et al., 1999) where the permeated macrophages engulf 
injured cells, including ox-LDL. Macrophages have the ability to uptake ox-LDL in an 
unregulated manner which can lead to the development of lipid-laden macrophages, 
termed foam cells (Dhaliwal & Steinbrecher, 1999). Foam cells also have the potential to 
release inflammatory cytokines and ROS, further damaging surrounding endothelial and 
smooth muscle cells. This vicious inflammatory cycle can continue with more LDL 
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penetration beneath the endothelium, its subsequent oxidation, and further foam cell 
activation. The accumulation of lipid-laden foam cells creates fatty streaks below the 
endothelium. Fatty streaks can enlarge and progress into fibrous plaque that protrudes 
into the arterial lumen, compromising the delivery of blood to distal tissues. Fibrous 
plaque can become unstable, rupturing and exposing the underlying tissue to the 
bloodstream. The ruptured and exposed plaque can then initiate platelet adhesion and the 
clotting cascade, rapidly forming a thrombus or embolus. The sudden occlusion of the 
distressed vessel can result in potentially lethal ischemia and infarction. Undoubtedly, the 
development of this vascular pathology would not take place without ox-LDL, which has 
been implicated in the initiation and exacerbation of lesion formation. As such, the core 
of atherosclerotic plaque is primarily comprised of ox-LDL derived lipid (Stary, et al., 
1995; Yla-Herttuala, et al., 1989). 
The oxidative modification of LDL. 
Although not yet proven, most researchers believe that LDL becomes oxidized 
within the arterial wall (Matsuura, Hughes, & Khamashta, 2008). It is within the 
subendothelial space that LDL may be exposed to a higher degree of oxidative stress as 
compared to the circulation. The bidirectional passage of LDL across the endothelium 
most likely accounts for presence of ox-LDL within the circulation. Under conditions of 
oxidative stress, several components of the LDL complex can be augmented by ROS. 
The polyunsaturated fatty acid portion of esterified cholesterol, phospholipids, and 
triglycerides are the most susceptible to oxidation (Itabe, 2009). The products of ROS 
induced lipid oxidation can participate in a chain reaction that propagates further lipid 
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modification. A variety of smaller fragments can be produced, including aldehydes. 
These aldehyde compounds have the capacity to modify the lysine, cysteine, histidine, 
and tryptophan amino acids of apoB-100 (Itabe, 2009). The accumulation of oxidized 
cholesterol, phospholipids, and triglycerides and their subsequent propagation into 
aldehydes is believed to be the primary pathway by which apoB-100 becomes modified. 
Another pathway has also been shown to modify apoB-100 in a more direct manner. 
Myeloperoxidase (MPO), an enzyme released from activated phagocytes, is capable of 
directly modifying apoB-100-assocated tyrosine (Podrez, Abu-Soud, & Hazen, 2000). 
The augmentation of the apoB-100 leaves LDL unrecognizable by LDL receptors. 
However antibodies and phagocytic cells, which are capable of recognizing the modified 
lipids and proteins of ox-LDL, act to remove the altered particle (Lopes-Virella & 
Virella, 2010; Shashkin, Dragulev, & Ley, 2005). In addition, ox-LDL has been reported 
to be cleared from circulation by hepatic Kuppfer cells (Ling, et al., 1997).  
Measurement of lipid and protein oxidation and antioxidant capacity. 
Exercise and health related studies have employed several types of measurements 
to assess protein and lipid oxidation and antioxidant capacity of the blood. A brief 
description of these types of measures is presented below.  
Ox-LDL concentration - This is the most direct measurement of circulating ox-LDL. This 
enzyme linked immunosorbent assay (ELISA) involves the spectrophotometric detection 
of ox-LDL after it has bound to a microplate labeled for oxidized apolipoprotein B, the 
dysfunctional form of the principle ligand for LDL receptors.  
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Ox-LDL lag time - This technique assesses the susceptibility of LDL to oxidation.  
Isolated LDL particles are subjected to in vitro oxidation, usually through a copper ion 
system. The time to oxidation, usually measured by the development of oxidized lipids, is 
determined. In this technique, a decrease in lag time (time to oxidation) is an indicator 
that the LDL particle is more susceptible to oxidation.  Conversely, an increase in lag 
time is an indicator that the LDL particle is less susceptible to oxidation.  
Conjugated dienes - When a polyunsaturated fatty acid comes under attack by an ROS a 
hydrogen atom is removed, resulting is a molecular rearrangement of the fatty acid 
structure. The result is the formation of a conjugated diene and is considered the initial 
step in lipid peroxidation. Serum and/or plasma conjugated dienes can be assessed as well 
as LDL associated conjugated dienes.  
Lipid hydroperoxides - A conjugated diene can readily react with an oxygen molecule 
forming a peroxyl- fatty acid radical. A peroxyl-fatty acid radical is an unstable species 
and can abstract a hydrogen atom from a polyunsaturated fatty acid forming a conjugated 
diene and a lipid hydroperoxide. Ultimately, lipid hydroperoxides represent further 
propagation of the lipid peroxidation process.  
Malonaldehyde, ethane and pentane - Lipid hydroperoxides can decompose through a 
complex process resulting in the formation of fatty acid fragmentation products. These 
products include aldehydes such as malonaldehyde (MDA) and short chain alkanes such 
as ethane and pentane. Consequently MDA, ethane and pentane have been assessed as 
biomarkers for latter stage lipid peroxidation.    
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Antibodies against Ox-LDL- The modified lipids, phospholipids and proteins associated 
with ox-LDL are highly immunogenic. The titer of antibodies against oxidized LDL can 
be evaluated as an indirect biomarker for the presence of ox-LDL.   
Protein Carbonyl Concentration – The abundant protein structures found in the blood are 
also susceptible to ROS attack. ROS interaction with an amino acid can transform the 
side chain amine group into a carbonyl. Measurement of protein carbonyl concentration 
within the serum or plasma is commonly used as a general oxidative stress marker. 
Total Antioxidant Capacity –The sum of the individual antioxidant substances found in 
the blood represents the overall ability of the antioxidant system. The antioxidant 
capacity can temporarily decrease in response to acute exercise as the components of the 
antioxidant system are used to diminish harmful ROS. Therefore, the degradation of the 
total antioxidant capacity can be used as an indicator of oxidative stress.  
Relationship between circulating ox-LDL and CVD. 
As mentioned above, the majority of LDL oxidation likely occurs within the 
arterial wall, as opposed to the antioxidant-rich environment of the blood (Frei, Stocker, 
& Ames, 1988).  In addition, the proportion of ox-LDL to total LDL is very small, 
ranging from 0.013% in controls to 0.027% in CAD patients in one study (Holvoet, et al., 
2001). Nonetheless, a growing body of evidence indicates a pathological role of 
circulating ox-LDL in the progression of atherosclerosis.   
Several studies have found that a high level of plasma ox-LDL is associated with 
a number of cardiovascular diseases. Coronary artery disease (CAD) patients, particularly 
those with acute coronary syndrome (Ehara, et al., 2001; Tsimikas, et al., 2003), have 
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presented with significantly elevated values of ox-LDL (Holvoet, et al., 2001; Tanaga, et 
al., 2002). Ox-LDL was also shown to be a prognostic marker for future CAD after heart 
transplantation (Holvoet, Van Cleemput, Collen, & Vanhaecke, 2000). In addition, 
atherosclerosis of the carotid artery (Nishi, et al., 2002) and ischemic stroke (Uno, 
Kitazato, Nishi, Itabe, & Nagahiro, 2003) have been reported to be associated with high 
plasma concentrations of ox-LDL. Taken together, these results point toward the use of 
ox-LDL as a biomarker for the presence of advanced atherosclerosis.  
Circulating ox-LDL has been identified as a predictor of future cardiovascular 
events in individuals with documented CVD (Shimada, et al., 2004), as well as re-
stenosis following coronary stenting (Naruko, et al., 2006).  Compared to the traditional 
lipoprotein profile and other traditional risk factors, ox-LDL was the strongest predictor 
of a future coronary event in apparently healthy men (Meisinger, Baumert, Khuseyinova, 
Loewel, & Koenig, 2005). In addition, a 10 year prospective study found that circulating 
oxidized phospholipids/apoB-100 ratio predicted cardiovascular events independent of 
traditional risk factors, highly sensitive C-reactive protein, and Framingham Risk Score 
(Kiechl, et al., 2007).Other evidence indicates that plasma ox-LDL plays a role in 
endothelial dysfunction (Penny, et al., 2001) and vasomotor function (Tamai, et al., 1997) 
in individuals with hypercholesterolemia, but without apparent atherosclerosis. 
In a case-control study, Cominacini et al. (2005) assessed the association between 
ox-LDL and inflammation in patients with angina pectoris. They found that circulating 
ox-LDL and blood mononuclear NF-κB levels were higher in the patients compared to 
controls. In addition, the in vitro incubation of high dose ox-LDL or serum from the 
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angina patients increased NF- κB in mononuclear cells. The authors concluded that 
circulating ox-LDL was responsible, at least in part, for the NF- κB activation, and thus, 
the elevated inflammation and oxidative stress in the angina pectoris patients. A recent 
study demonstrated the direct effect of ox-LDL removal from circulation on the 
development and progression of atherosclerosis (Ishigaki, et al., 2008). Lectin-like ox-
LDL receptor 1 (LOX-1) is an ox-LDL receptor found on endothelial cells, macrophages, 
smooth muscle cells and atherosclerotic lesions in humans (Kume, et al., 1998). LOX-1 is 
a scavenger receptor that selectively binds and removes ox-LDL from the circulation 
(Sawamura, et al., 1997). Therefore, to remove circulating ox-LDL, LOX-1 was 
ectopically expressed in the liver of apolipoprotein E (apoE) deficient mice with an 
adenoviral gene transfer system. Although plasma total cholesterol, triglycerides and 
LDL cholesterol were unaltered, plasma ox-LDL was significantly reduced in the hepatic 
LOX-1 mice compared to controls. In addition, monocyte chemotactic protein-1 and lipid 
peroxide levels were decreased while adiponectin increased, suggesting a reduction of 
systemic oxidative stress in LOX-1 mice. Most importantly, LOX-1 expression almost 
completely prevented atherosclerosis progression, while controls displayed significant 
atherosclerotic lesions. This investigation dramatically demonstrated the affect of 
circulating ox-LDL on atherosclerosis development, independent of other blood lipid 
markers.   
Although the extent of the contribution of circulating ox-LDL to atherosclerotic 
advancement is not fully known, many research studies have shed light on its 
pathological involvement. Ox-LDL removal is now a therapeutic target in the prevention 
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of cardiovascular diseases. Investigations targeting the degradation or removal of ox-
LDL from circulation are receiving considerable attention as a treatment strategy for 
atherosclerosis (Ishigaki, Oka, & Katagiri, 2009). More information needs to be collected 
concerning the receptors and antioxidants responsible for the clearance of ox-LDL from 
the circulation.  
 
Paraoxonase 1 
 Paraoxonase 1 (PON1) is a calcium-dependent A-esterase enzyme that is 
synthesized and secreted primarily from the liver. The name paraoxonase is derived from 
paraoxon, the first organophosphate (OP) substrate revealed to be hydrolyzed by the 
enzyme (Aldridge, 1953). Originally, PON1 was investigated due to its ability to 
hydrolyze toxic OP insecticides such as parathion (metabolized to paraoxon) (Aldridge, 
1953; Geldmacher-v Mallinckrodt, Hommel, & Dumbach, 1979; Playfer, Eze, Bullen, & 
Evans, 1976), chlorpyrifos (Furlong, Richter, Seidel, Costa, & Motulsky, 1989; Furlong, 
Richter, Seidel, & Motulsky, 1988), and diazinon (Davies, et al., 1996). In addition 
PON1 was found to be capable of degrading the nerve toxins soman and sarin (Smolen, 
Eckerson, Gan, Hailat, & La Du, 1991). These features made PON1 an obvious topic of 
research in the areas of agriculture and biological warfare. Indeed, in animal and human 
studies PON1 activity was shown to correlate well with OP insecticide and nerve gas 
sensitivity. Rabbits, which have higher PON1activity than rats, are more resistant to 
insecticide poisoning than rats (Costa, Richter, Murphy, & Omenn, 1987). Furthermore, 
the intravenous administration of purified PON1 to PON1 null mice improved protection 
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against insecticide poisoning (Li, et al., 2000; Stevens, et al., 2008). In Gulf War 
veterans, low PON1 activity has been shown to be associated with greater neurological 
symptoms from possible toxic nerve gas exposure (Furlong, 2000; Haley, Billecke, & La 
Du, 1999). As a result of such studies, PON1 is currently a prime target of research for 
human medical treatment of insecticide and nerve agent exposure (Boado, Zhang, Zhang, 
Wang, & Pardridge, 2008; Rochu, Chabriere, & Masson, 2007; Yair, et al., 2008). 
More recently PON1 has drawn attention as an antioxidant and anti-inflammatory 
agent. Low PON1 enzymatic activity has been associated with several disease states that 
share the common theme of oxidative stress. These pathologies include types 1 and 2 
diabetes (Abbott, Mackness, Kumar, Boulton, & Durrington, 1995; B. Mackness, 
Durrington, Boulton, Hine, & Mackness, 2002; B. Mackness, et al., 1998), chronic renal 
failure (Dantoine, et al., 1998), uremia (Biasioli, et al., 2003), thyroid dysfunction (Azizi, 
et al., 2003), rheumatoid arthritis (Tanimoto, et al., 2003),multiple sclerosis (Ferretti, et 
al., 2005), metabolic syndrome (Sentí, et al., 2003), hyperlipidemia (Paragh, et al., 1998), 
and coronary artery disease (B. Mackness, et al., 2003). 
Since the oxidative modification of LDL is the leading theory describing the 
relationship between elevated LDL and atherosclerosis, PON1 has recently become an 
enzyme of great interest in the CVD research. Several studies have demonstrated that 
PON1 can inhibit the oxidation of LDL and hydrolyze LDL-derived lipids once they are 
formed (see below). These investigations have led several authors to suggest that the 
natural physiological function of PON1 is to hydrolyze oxidized lipids, thus serving as a 
cardioprotective antioxidant (Camps, et al., 2009; James, 2006). The antioxidant capacity 
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of PON1 has also made it an optimistic target for CVD prevention and treatment (Costa, 
Cole, Jarvik, & Furlong, 2003; Durrington, Mackness, & Mackness, 2002). Claims 
concerning PON1’s ability to hydrolyze these specific oxidized lipids have not been fully 
substantiated and needs further study. In addition, the relationship between oxidized LDL 
and PON1 has not been fully described; information concerning this relationship could 
prove to be very important in the prevention of CVD.    
PON1 level is typically measured as either enzymatic activity and/or protein 
concentration in the serum. PON1 can hydrolyze several substrates including paraoxon, 
phenylacetate, diazoxon, and several lactones, all of which have been used to describe 
PON1 activity (Table 1). PON1’s versatility is a feature that researchers have labeled as 
“catalytic promiscuity” due to its broad range of substrate partners (Bornscheuer & 
Kazlauskas, 2004; Copley, 2003; O'Brien & Herschlag, 1999). Investigations have 
utilized this variety of substrates to assess PON1 activity and there is no consensus as to 
which substrate is more appropriate. PON1 enzyme concentration can also indicate the 
level of protective potential; however most exercise studies have chosen to assess PON1 
quality (activity) as opposed to the quantity (concentration). 
PON1 association with HDL. 
PON1 is an enzyme with a molecular mass of 43-45 kDa (354 amino acids) 
(Blatter, James, Messmer, Barja, & Pometta, 1993; Gan, Smolen, Eckerson, & La Du, 
1991). It is produced and secreted primarily from the liver. The production and secretion 
from the hepatocytes is the largest determinant of serum PON1 level. There is 
considerable variability in the serum concentration and activity of PON1 among 
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Table 1. Summary of Methods for Determination of PON1 Enzymatic Activity 
Substrate Activity 
Paraoxon Paraoxonase(esterase) 
 
Phenylacetate Arylesterase 
Diazoxon Diazoxonase (esterase) 
Soman Esterase 
Sarin Esterase 
Homocysteinethiolactone 
 
Lactonase 
5-thiobutyl butyrolactone (TBBL) Lactonase 
7-O-diethyl phosphoryl 
3-cyano 4-methyl 7-
hydroxycoumarinDEPCyMC 
 
Lactonase 
Adapted from Camps, et al(2009). 
  
individuals. These variations are a result, to some extent, of several polymorphisms in the 
coding and promoter regions of the PON1 gene (Adkins, Gan, Mody, & La Du, 1993; 
Humbert, et al., 1993; Leviev & James, 2000; Suehiro, et al., 2000). PON1’s production 
leaves the peptide with a highly hydrophobic N-terminal region (Sorenson, et al., 1999). 
Therefore, it requires the proper vector to be transported within the aqueous environment 
of the blood. Deakin et al.(2002) demonstrated that the most suitable acceptor of PON1 is 
a lipid complex, with HDL having the highest affinity for PON1. HDL is believed to 
transiently bind to the hepatocyte, possibly via SR-B1 (Acton, et al., 1996), where PON1 
is transferred to the lipoprotein. Apo A1, the major protein component of HDL, is most 
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likely responsible for the binding process and is very important for the enzymatic 
stability of PON1 in the circulation (Deakin, et al., 2002; James, et al., 1998; Sorenson, et 
al., 1999). Although PON1in the circulation is exclusively bound to HDL, evidence 
suggests that it is only found on approximately 10% of circulating HDL (Blatter, et al., 
1993; Kelso, et al., 1994). 
Modulation of PON1 activity. 
Drugs. 
Most studies assessing the effects of pharmaceutical agents and PON1 were done 
so using lipid-lowering statins and fibrates. These studies have yielded conflicting results.  
PON1 activity increased in patients taking statins, gemfibrozil and fenofibrate (Balogh, et 
al., 2001; Deakin, Leviev, Guernier, & James, 2003; Jarvik, et al., 2002; Paragh, et al., 
2003).  Deakin et al. (2003) found that simvastatin increased PON1 promoter activity by 
increasing sterol regulatory element binding protein 2, however these results were 
contradicted in another study which demonstrated diminished promoter activity after 
treatments of simvastatin, pravastatin, and fluvastatin (Gouedard, Koum-Besson, 
Barouki, & Morel, 2003). Patients treated with ciprofibrate, bezafibrate, and gemfibrozil 
have shown no change in PON1 activity (Durrington, et al., 1998; Turay, Grniakova, & 
Valka, 2000). In addition, CAD patients utilizing aspirin as a therapeutic agent displayed 
increased PON1 activity and concentration (Blatter-Garin, Kalix, De Pree, & James, 
2003). This could be due to the anti-inflammatory effect of aspirin or the modulation of 
PON1 production. Human hepatic cells displayed a significant induction of PON1 gene 
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expression after incubation with aspirin in vitro (Jaichander, Selvarajan, Garelnabi, & 
Parthasarathy, 2008).   
Smoking. 
Several studies have reported an association between cigarette smoking and low 
PON1 activity (Ferre, et al., 2003; James, Leviev, & Righetti, 2000; Jarvik, et al., 2002; 
Senti, et al., 2003). This effect is apparently short-lived, as one study reported a return to 
control PON1 level 3-24 months after smoking cessation (James, et al., 2000). This 
finding suggests that cigarette smoke directly effects PON1 activity, which is supported 
by in vitro evidence (Nishio & Watanabe, 1997). 
Alcohol Consumption. 
Studies involving middle-aged men and postmenopausal women found that 
moderate consumption of beer, wine, or spirits for 3 weeks increased PON1 activity 
(Sierksma, van der Gaag, van Tol, James, & Hendriks, 2002; van der Gaag, et al., 1999).  
Heavy drinking has been shown to adversely affect PON1 activity. Rao et al. (2003) 
found that heavy drinkers had a 45% lower, but moderate drinkers had a 395% higher 
PON1 activity compared to non-drinkers. Despite evidence that moderate alcohol 
consumption can increase PON1 activity, several studies have concluded that alcohol has 
no effect on PON1 (Ferre, et al., 2003; Sarandol, Serdar, Dirican, & Safak, 2003; 
Vincent-Viry, et al., 2003). 
Diet. 
Although the evidence is not conclusive, the research suggests that high fat diets 
and trans fat diets tend to decrease PON1 activity while unsaturated fat intake tends to 
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increase PON1 activity. Male and female rats on a high fat diet for 14 weeks had 
decreased PON1 activity compared to controls (Thomas-Moya, Gianotti, Proenza, & 
Llado, 2007). Another study found that replacement of dietary saturated fat with trans fat 
resulted in a 6% reduction in PON1 activity in healthy men and women (de Roos, 
Schouten, Scheek, van Tol, & Katan, 2002). Data from a 72-hour dietary recall 
questionnaire showed that consumption of oleic acid, a monounsaturated fatty acid, was 
associated with higher PON1 activity in 654 men, but only those with a QR or RR 
genotypes of PON1(Tomas, et al., 2001). In addition, administration of omega-3 
polyunsaturated fatty acid capsules to 14 patients with combined familial hyperlipidemia 
resulted in a 10% increase in PON1 concentration after 8 weeks (Calabresi, et al., 2004).  
It should also be noted that administration of partially hydrogenated soybean, soybean, 
palm, or canola oil for 5 weeks revealed no differences in PON1 activity in men and 
women over 50 (Vega-Lopez, Ausman, Jalbert, Erkkila, & Lichtenstein, 2006). 
Antioxidant and PON1 investigations have yielded contrasting results. 
Consumption of pomegranate juice for 2 weeks increased PON1 activity by 18% in 13 
healthy men (Aviram, Dornfeld, et al., 2000). Pomegranate juice was also responsible for 
increased PON1 binding to HDL in individuals with diabetes (B. Fuhrman, Volkova, & 
Aviram, 2009). Vitamins C and E were assessed via recall questionnaire with 189 men 
and revealed that intake of these antioxidant vitamins were significant positive predictors 
of PON1 activity (Jarvik, et al., 2002). On the contrary, two studies have reported 
negative associations between fruit and/or vegetable intake (high in vitamins C and E) 
and PON1 activity (Kleemola, et al., 2002; Rantala, et al., 2002). In addition, Ferre et al. 
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(2003) found no association between vitamins C and E and beta carotene intake and 
serum PON1 activity in 388 men and women. Obviously, the interaction between dietary 
antioxidants and serum PON1 activity necessitates further study.  
Hepatic Regulation. 
 PON1 modulation at the cellular level of the hepatic cells has been examined in a 
limited number of studies. Although the evidence is small, investigations agree that 
PON1 gene expression is dependent on the aryl hydrocarbon receptor (AhR), a cytosolic 
transcription factor. The antioxidants quercetin and resveratrol significantly increased 
PON1 gene expression via an AhR dependent mechanism after in vitro incubation with 
HuH7 cells (Gouedard, Barouki, & Morel, 2004a, 2004b). PON1 gene expression 
increased significantly in human hepatoma cells (HepG2) following incubation with 
aspirin in vitro (Jaichander, et al., 2008). The up-regulation of the PON1 gene was 
associated with induction of AhR gene expression, a suspected receptor of aspirin 
metabolites. In addition, one investigation reported that activation of transcription factor 
Sp1 and protein kinase C were involved in PON1 promoter activity in HepG2 cells 
(Osaki, et al., 2004).  
Oxidative Stress. 
As mentioned previously, several disease states associated with increased 
oxidative stress are also associated with decreased PON1 activity. Precisely how this 
relationship occurs is not clear. Oxidation products could either down-regulate the gene 
expression of PON1 or negatively affect PON1 within the circulation. One in vitro study 
demonstrated that a variety of oxidized lipids, including ox-LDL, inactivated PON1 
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activity after their co-incubation (Aviram, et al., 1999). This information implies that 
PON1 loses its functional ability in the bloodstream upon interaction, and subsequent 
hydrolysis, of its target. The incubation in this study was performed for 18 hours, which 
additionally suggests that the degradation of PON1 could be a chronic effect of the 
oxidized lipids within the circulation. This mechanism, although not conclusive, suggests 
that systemic degradation of PON1 activity explains the connection between chronic 
oxidative stress and many pathophysiologies.   
Similarly, very little is known about how oxidative stress affects hepatic PON1 
synthesis, release, and binding to HDL, features that could also influence PON1 activity. 
Only one investigation has examined how one of PON1’s primary targets, oxidized 
lipids, affects the hepatocyte itself. Navab et al. (1997) found that incubation of ox-LDL 
with HepG2 cells for 16 hours reduced PON1 mRNA by 3-fold. Based off of limited 
evidence, it seems that constant exposure of ox-LDL to PON1 and hepatic cells results in 
the loss of activity and expression of PON1, respectively. However, what remains to be 
investigated is the acute phase response of the PON1 protein and the hepatocyte to the 
sudden increase in ox-LDL concentration.  
PON1 and CVD. 
In Vitro Studies. 
There is a well-established negative relationship between HDL concentration and 
incidence of CVD. Several prominent studies have shown that individuals with low HDL 
are more prone to CVD events than individuals with high HDL (ATP-III, 2002). While 
HDL’s primary cardio-protective role is widely attributed to reverse cholesterol transport, 
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HDL also exhibits anti-inflammatory, antithrombotic, and antioxidant properties that 
provide cardiovascular benefits (Florentin, Liberopoulos, Wierzbicki, & Mikhailidis, 
2008). The antioxidant activity of HDL is largely attributed to the activity of PON1, as a 
large body of evidence has demonstrated that PON1 disrupts many of the pro-oxidant 
processes involved in atherogenesis.   
Given the established negative association between HDL and atherosclerosis, and 
encouraged by evidence that HDL could inhibit the oxidative modification of LDL 
(Parthasarathy, Barnett, & Fong, 1990), Mackness et al. (1991) attempted to further 
define the interaction between HDL and LDL in atherosclerosis. The HDL-associated 
enzyme PON1 was suspected to play a part in the antioxidant properties displayed by 
HDL. LDL that had been oxidized through copper exposure was incubated with native 
HDL and purified PON1. The researchers found that HDL and PON1 prevented 
lipoperoxide generation to a similar extent, implying that the PON1 enzyme was involved 
in the antioxidant effects observed by HDL. This was the first study to indicate that 
PON1 protected LDL from potentially atherogenic oxidation and thus pointing to its 
involvement with CVD. The discovery of this feature of PON1 shed new light on 
thecardioprotective role of HDL. For the next two decades the direction of PON1 
research focused primarily on its connection with the oxidation and inflammatory 
processes thought to mediate the arterial plaque development.  
In vitro experiments with LDL and PON1 have typically involved the isolation of 
LDL, followed by oxidation induced via copper ions or ROS-generated processes. These 
processes were conducted either with or without the addition of purified PON1.These 
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experiments have shown that the addition of PON1 greatly decreased LDL-associated 
accumulation of oxidized lipids such as lipid peroxides (Aviram, Billecke, Sorensen, et 
al., 1998; Bianca Fuhrman, Volkova, & Aviram, 2005; B. Mackness, Hine, Liu, 
Mastorikou, & Mackness, 2004; B. Mackness, Mackness, Arrol, Turkie, & Durrington, 
1998; M. Mackness, Arrol, Abbott, & Durrington, 1993), lipid hydroperoxides (Navab, 
Hama, Cooke, et al., 2000), and aldehydes (Aviram, Billecke, Sorensen, et al., 1998; 
Bianca Fuhrman, et al., 2005). These oxidized lipids are believed to cause oxidative 
modification of the phospholipid component of LDL, ultimately modifying the 
particle’sapoB-100 protein and disrupting LDL function. Specifically, PON1 has been 
shown to destroy the lipid hydroperoxides hydroperoxyoctadecadienoic acid (HPODE), 
hydroperoxyeicosatetraenoic acid (HPETE), and cholesteryl hydroperoxide (CE-OOH) 
(Navab, Hama, Cooke, et al., 2000).In addition, experiments have demonstrated that 
PON1 can inactivate oxidized phospholipids once they form within the LDL particle, 
specifically 1-palmitoyl-2-oxovaleryl-sn-glycero-3-phosphocholine (POVPC), 1-
palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC), and 1-palmitoyl-2-(5, 6-
epoxyisoprostane E2)-sn-glycero-3-phosphocholine (PEIPC) (Navab, Hama, 
Anantharamaiah, et al., 2000; Navab, Hama, Cooke, et al., 2000; A. D. Watson, et al., 
1995). Oxidized phospholipids are the primary oxidized lipid found within oxidized LDL 
and are believed to initiate the inflammatory cell signaling cascade. Essentially, the 
hydrolyzing action of PON1 toward the oxidized lipids can protect LDL from apoB-100 
modification, thus retaining the particle’s native, functional state. 
 
 
30 
Ex Vivo Studies. 
In addition, researchers have examined PON1’s role in the LDL-endothelial 
interaction with ex vivo cultures of endothelial cells of human carotid, aortic, or coronary 
arteries. Navab, Hama, Cooke, et al.(2000) found that incubation of LDL particles with 
PON1 rendered them resistant to oxidation by aortic/smooth muscle cell cultures.  
Similarly, when aortic cultures where incubated with PON1 prior to LDL introduction, 
the cultures were incapable of oxidizing LDL (Navab, Hama, Anantharamaiah, et al., 
2000). These studies suggest that PON1 reduces ROS generation from the artery wall, 
which is believed to be the primary avenue by which LDL molecules become oxidatively 
modified. This antioxidant property was further supported by evidence that PON1 can 
hydrolyze hydrogen peroxide (Aviram, Rosenblat, et al., 1998), a major ROS produced 
by endothelial cells and phagocytes under oxidative stress. Evidence has also shown that 
PON1 can reduce cholesteryl ester hydroperoxides and cholesteryl ester peroxides from 
carotid and coronary artery atherosclerotic lesions (Aviram, Hardak, et al., 2000). Figure 
1 demonstrates the theoretical protective mechanisms by which PON1 preserves LDL 
from oxidation.  
The PON1-induced blockage of LDL oxidation has also been shown to disrupt 
further steps in foam cell formation. After mildly oxidized LDL or artery wall cultures 
were incubated with PON1, they were unable to induce monocyte chemotaxis and 
binding to endothelial cells (Navab, Hama, Anantharamaiah, et al., 2000; Navab, Hama, 
Cooke, et al., 2000; A. D. Watson, et al., 1995). This inhibition of monocyte cell 
signaling was apparently caused by the ability of PON1 to inhibit the biological 
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Ox-LDL 
Ox-phospholipids 
Figure 1. PON1 Prevention of LDL Oxidation 
             
 
 
 
 
 
 
       
 
 
 
______________________________________________________________________________________ 
PON1 Prevention of LDL Oxidation.PON1 can prevent the oxidation of LDL from hydrogen peroxide 
(H2O2), lipid hydroperoxides, lipid peroxides, and aldehydes.  PON1 can also hydrolyze oxidized 
phospholipids within oxidized LDL (ox-LDL).  Although depicted within the artery wall, this process is 
believed to occur in the circulation as well. Adapted from Camps, et al.(2009) and Navab, Hama, 
Anantharamaiah, et al.(2000). 
 
 
activity of oxidized phospholipids (Navab, Hama, Anantharamaiah, et al., 2000; A. D. 
Watson, et al., 1995) which in turn, inhibited NF-κB activation and the production of 
cytokines (e.g. IL-8, M-CSF), chemokines (e. g. MCP-1 ), and adhesion molecules (e. g. 
VCAM-1, ICAM-1) (Aviram & Rosenblat, 2004; B. Mackness, et al., 2004; Navab, et al., 
2001; Negre-Salvayre, et al., 2006).  
In addition to attenuating foam cell generation through prevention of LDL 
oxidation, PON1 may also prevent HDL oxidation and aid in its reverse cholesterol 
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transport function. Aviram, Rosenblat, et al. (1998) found that HDL-associated PON1 
was very important in the maintenance of the lipoprotein’s cholesterol accumulation. The 
addition of PON1 to purified HDL extended oxidation lag phase time and reduced lipid 
peroxide and aldehyde accumulation by 95%, demonstrating that PON1 confers a 
significant antioxidant role to HDL. In addition, compared to oxidized untreated HDL, 
oxidized PON1-treated HDL caused a significant increase in cholesterol efflux from J-
744 A.1 macrophages. This suggests that PON1’s protection from HDL oxidation 
preserves its ability to receive cholesterol and remove it from circulation.   
Animal Models. 
Perhaps the most powerful evidence that PON1 protects the vasculature from 
atherosclerotic development comes from rodent models. Studies examining the effects of 
PON1 generally involve either the suppression or overexpression of the enzyme. These 
studies have not only identified differences in arterial plaque formation, but differences in 
atherosclerotic processes such as oxidative stress and adhesion molecule expression. 
Shih, et al. (1998) found that when fed a high-fat, high cholesterol diet, PON1 knockout 
(KO) mice had significantly larger aortic lesions compared to the wild-type littermates. In 
two studies, atherogenesis was compared between atherogenic-prone apolipoprotein E 
(apoE) KO mice and mice with a combined apoE KO/PON1 KO genotype (Rozenberg, 
Rosenblat, Coleman, Shih, & Aviram, 2003; Shih, et al., 2000). In both cases, the apoE 
KO/PON1 KO displayed more atherosclerosis than the apoE KO genotype alone. In 
addition, Rozenberg and colleagues (2003) showed that PON1 deficiency resulted in 
increased arterial and macrophage oxidative stress, processes that can contribute to 
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plaque formation. Furthermore, increases in adhesions molecules, vascular oxidative 
stress, and carotid thrombosis were observed by Ng, et al. (2008) in PON1-null mice fed 
a regular chow diet. 
Conversely, mice that overexpress PON1 typically exhibit less atherosclerosis. 
Human PON1 transgenic (Tg) mice, which displayed a significant increase in plasma 
PON1 activity, had reduced atherosclerotic lesions even when high fat diet and apoE KO 
mouse models were examined (She, et al., 2009; Tward, et al., 2002). Plaques from the 
PON1 Tg/apoE KO mice also appeared to be more stable, as collagen and smooth muscle 
were increased and macrophage and lipid were decreased within the lesions (She, et al., 
2009). Likewise, macrophage and aortic-derived oxidative stress, as well as 
atherosclerotic lesion size, were reduced in human PON1 Tg mice (Rozenberg, Shih, & 
Aviram, 2005). Overexpression of human PON1 has also been shown to reduce plaque 
progression in mice with combined leptin and LDL receptor deficiency, a model for 
metabolic syndrome (B. Mackness, Quarck, Verreth, Mackness, & Holvoet, 2006). In a 
study examining apoE KO, older mice (18 months) with advanced atherosclerosis, 
Gunset al. (2008) transfected the subjects with a PON1 adenovirus. The 13-15 fold 
increase in PON1 activity did not affect lesion size, but did decrease vascular oxidative 
stress, and improved endothelial and smooth muscle cell function. This study 
demonstrated that PON1 can improve vasomotor function, independent of plaque size, in 
older mice with preexisting atherosclerosis. 
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Epidemiological and Longitudinal Studies. 
Several epidemiological studies have investigated the relationship between PON1 
and risk, or incidence, of CVD in humans. Particularly interesting evidence emphasizing 
the importance of PON1 came from Navab et al.(1997), who showed that individuals 
with normal HDL concentration, but low PON1 activity, were more susceptible to 
atherosclerosis than individuals with normal HDL and significantly higher PON1 
activity. Several other case-control investigations demonstrated a significant inverse 
relationship between CVD or its risk factors and PON1 activity and concentration (Ayub, 
et al., 1999; Jarvik, et al., 2000; B. Mackness, et al., 2001; McElveen, et al., 1986; Yildiz, 
et al., 2008), but none of these studies were able to indicate if low PON1 status was a 
cause or a result of CVD. This distinction can only be elucidated from longitudinal 
investigations.  
 In a recent 3-4 year longitudinal study, Bhattacharyya and colleagues (2008) 
assessed 1399 individuals participating in the GeneBank study who had undergone an 
elective diagnostic coronary angiography. This study revealed an inverse relationship 
between CVD prevalence and serum paraoxonase levels. Low levels of PON1 activity 
were significantly associated with the presence of coronary artery disease (paraoxonase: 
OR (odds ratio), 1.5; 95% CI, 1.03-2.3; p=.03; arylesterase: OR, 2.0; 95% CI, 1.4-
3.1;p=.001]. By follow-up, the frequency of nonfatal MI or stroke among individuals 
within the highest quartiles of PON1 activity was only 2.5% (8/315) with paraoxonase 
activity and 2.8% (9/324) with arylesterase activity. The frequency of nonfatal MI or 
stroke within the lowest quartiles of PON1 activity was 11.9% (37/311) with paraoxonase 
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and 12.5% (40/319) with arylesterase activity. In addition, the researchers observed an 
all-cause mortality incidence of 5.4% (17/315, paraoxonase activity) and 4.9% (16/324, 
arylesterase activity) within the highest quartiles of PON1 activity compared to 11.9% 
(37/311, paraoxonase activity) and 12.9% (41/319, arylesterase activity) within the 
lowest quartiles. In the Caerphilly Prospective Study, 1353 men aged 49 to 65 years were 
monitored for coronary heart disease (CHD) events for a mean period of 15 years. The 
PON1 activity of the 163 participants who experienced a coronary event was 20% lower 
(p= 0.039) than the men who did not. Quintiles comparing PON1 activity to CHD risk 
showed an inverse, graded relationship with the median change in OR across each 
quintile being 0.87 (0.77 to 0.98). The results indicated that PON1 activity was an 
independent predictor of a new coronary event in men with preexisting CHD or at high 
risk for CHD. Interestingly, in this investigation there was no relationship between PON1 
concentration and CHD (B. Mackness, et al., 2003).   
Epidemiological research supports the contention that atherogenesis is not only 
associated with, but possibly preceded by low PON1 activity. It is also important to note 
that in the above epidemiological and longitudinal studies significant relationships 
between PON1 activity and CVD were measured using a variety of substrates including 
paraoxon, phenylacetate, and diazoxon. Although more research is needed to establish a 
causative relationship, current evidence suggests that PON1 concentration and activity 
may be an important factor in the prevention of atherosclerosis.  
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Acute Exercise Studies and Oxidized Lipid and Protein 
 
The exercise paradox. 
 
It is well-recognized that many health benefits result from regular aerobic 
physical activity. More specifically, a lifestyle void of regular physical activity merits a 
risk factor for cardiovascular disease (ACSM, 2006). Of the many cardiovascular benefits 
afforded by chronic exercise, the reduction of circulating ox-LDL, LDL-associated 
oxidized lipids, and LDL susceptibility to oxidation have been well documented 
(Cornelissen, Arnout, Holvoet, & Fagard, 2009; R. Elosua, et al., 2003; Rector, et al., 
2007; Tomas, et al., 2002; Vasankari, Kujala, Vasankari, & Ahotupa, 1998; Ziegler, et 
al., 2006). With the evidence that regular physical activity acts as an antioxidant, one 
would expect that an isolated bout of physical activity would also serve as an antioxidant. 
On the contrary, an isolated bout of physical activity increases tissue utilization of 
oxygen and results in the propagation of free radicals (Fisher-Wellman & Bloomer, 
2009). With sufficient exercise intensity and duration, the ROS overwhelm the 
antioxidant defenses, leading to oxidative stress. The lipid and protein components of 
LDL can be subjected to the increased ROS attack causing their modification (see next 
section). The pro-oxidant nature of acute exercise and the antioxidant nature of chronic 
exercise have been labeled the “exercise paradox.” This can be a point of confusion due 
to the beneficial effects of chronic exercise but the seemingly deleterious effects of acute 
exercise. Many authors have concluded that the transient increase in oxidative stress 
stimulates an up-regulation of several antioxidant genes (Gomez-Cabrera, Domenech, & 
Vina, 2008; Parthasarathy, Santanam, Ramachandran, & Meilhac, 2000). Thus exercise 
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training appears to lead to adaptations of the endogenous antioxidant defense system 
(Knez, Jenkins, & Coombes, 2007; Powers, Ji, & Leeuwenburgh, 1999), ultimately 
leading to a decrease in ox-LDL in the chronic exerciser. Nonetheless, acute exercise 
models can be used to examine the response of the antioxidant system (genes, enzymes, 
etc.) to a sudden increase in oxidative stress, furthering our understanding of how the 
antioxidant system functions and adapts to exercise.  
Long duration exercise and ox-LDL. 
Long endurance exercise bouts such as half-marathons, marathons, and Iron Man 
triathlons have resulted in elevated plasma MDA (Child, Wilkinson, Fallowfield, & 
Donnelly, 1998; Neubauer, Konig, Kern, Nics, & Wagner, 2008), conjugated dienes 
(Neubauer, et al., 2008) and decreased LDL lag phase time (Kaikkonen, et al., 2002; Liu, 
et al., 1999).Elevated lipid oxidation markers have been found immediately after long 
duration events and up to 4 days after a marathon (Liu, et al., 1999). Other long duration 
endurance studies have examined individuals who completed the Scientific Race of the 
Sant Pau Hospital, an annual run performed for the purpose of collecting medical 
research. This 4 hour continuous run conducted with trained individuals has produced 
mixed results; decreases in LDL lag phase time and increases in electronegative LDL 
(Benitez, et al., 2002; Sanchez-Quesada, et al., 1995; Sanchez-Quesada, et al., 1998), but 
no changes in plasma and LDL associated MDA (Benitez, et al., 2002) or plasma and 
LDL associated TBARS (Sanchez-Quesada, et al., 1998). In addition, 8 males ran 31 km 
with an increase in serum conjugated dienes immediately afterward, but no change in 
LDL conjugated dienes (Vasankari, Kujala, Vasankari, Vuorimaa, & Ahotupa, 1997). 
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This same investigation found no changes in serum conjugated dienes or LDL conjugated 
dienes after a marathon run.   
Some investigations have reported diminished LDL associated lipid oxidation 
following particularly long duration exercise. Neubauer et al.(2008) found that ox-LDL 
decreased, but ox-LDL/LDL ratio tended to increase following an Iron Man triathlon. 
Vuorimaa, Ahotupa, Irjala, and Vasankari (2005) discovered decreased LDL-associated 
conjugated dienes after trained participants walked at 55% heart rate reserve for 6 hours.  
Twenty-six males and 13 females who completed the Hawaii Iron Man World 
Championship Triathlon showed a reduced susceptibility of plasma lipids to in vitro 
oxidation 15 minutes post-race (Ginsburg, et al., 1996).  After a marathon 46 males and 
females showed a decrease in oxidation susceptibility of serum lipids (Kaikkonen, et al., 
2002).   
Unfortunately, nearly all of the long duration exercise studies failed to control for 
exercise intensity and dietary factors, making the results difficult to compare. Overall, it 
seems that aerobic exercise of relatively long duration is sufficient to induce the 
oxidation of circulating lipids and LDL, but not all investigators agree. More well-
designed studies addressing the relationship between extended aerobic activity and 
oxidized lipids are warranted.  
Maximal exercise tests and ox-LDL. 
Ox-LDL and its associated measures in relation to maximal exercise tests are 
mixed, with investigations resulting in increased, decreased or no change in ox-LDL. 
LDL associated lipid peroxides were evaluated by Hsu, Lee, and Chen (2000) pre-, peak, 
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Table 2. Summary of Long Duration Exercise and Ox-LDL Studies 
Citation Exercise 
protocol 
Lipid oxidation 
markers 
Time points Results 
Child, et al., 
1998 
13.1 mile 
treadmill run 
Plasma-MDA Immediately pre 
& post 
↑ immediately 
post 
Neubauer, et al., 
2008 
Ironman 
Triathlon 
Plasma-MDA, 
plasma-CD, ox-
LDL 
concentration 
2 days pre and 
immediately, 1,5, 
&19 days post 
No change in 
ox-LDL, ↑ 
plasma-CD 
immediately & 
1 day post, ↑ 
plasma-MDA 
1 day post 
Kaikkonen, et al., 
2002 
Marathon VLDL + LDL 
susceptibility to 
oxidation, serum 
lipids 
susceptibility to 
oxidation 
Immediately pre 
& post 
↑ VLDL + 
LDL 
susceptibility 
to oxidation& 
↓ serum lipids 
susceptibility 
to oxidation 
Liu, et al., 1999 Marathon LDL 
susceptibility to 
oxidation 
Immediately pre 
and immediately 
& 4 days post 
 
↑ immediately 
& 4 days post 
Benitez, et al., 
2002 
4 hour run LDL 
susceptibility to 
oxidation, LDL(-
), LDL- & 
plasma-MDA 
Immediately pre 
& post 
↑ LDL 
susceptibility 
to oxidation 
and LDL(-). 
No change in 
LDL- and 
plasma- MDA 
Sanchez-
Quesada, et al., 
1995 
 
4 hour run LDL 
susceptibility to 
oxidation, e 
LDL(-) 
Immediately pre 
& post 
↑ LDL 
susceptibility 
to oxidation 
and LDL(-) 
Sanchez-
Quesada, et al., 
1998 
4 hour run LDL 
susceptibility to 
oxidation, LDL(-
), LDL- & 
plasma- TBARS 
Pre & between 
15-30 mins post 
↑ LDL 
susceptibility 
to oxidation 
and LDL(-). 
No change in 
LDL- & 
plasma- 
TBARS 
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Table 2. Summary of Long Duration Exercise and Ox-LDL Studies (Continued) 
 
 
Summary of Long Duration Exercise and Ox-LDL Studies. VLDL- very low density lipoprotein, LDL- low 
density lipoprotein, ox-LDL- oxidized low density lipoprotein, LDL(-) - electronegative LDL, MDA- 
malondialdehyde, CD- conjugated dienes, TBARS- thiobarbituric acid reactive substances, ↑- significant 
increase, ↓- significant decrease. 
 
and 10 minutes post- a treadmill maximal exercise test. Subjects were sedentary, non-
overweight/obese, and 41-59 years old. LDL lipid peroxides decreased during exercise, 
reaching statistical significance 10 minutes post-exercise. In another study, young non-
overweight subjects cycled on a leg ergometer at approximately 50% maximal oxygen 
consumption for 30 minutes daily, 5 days a week, for 8 weeks, then detrained for 12 
weeks. Every 4 weeks cycle ergometer max tests were performed with ox-LDL measured 
immediately before and after. There were no significant changes in ox-LDL after the max 
tests at any time point (J. S. Wang & Chow, 2004) . Immediately after a treadmill VO2 
max test congestive heart failure (CHF) patients experienced significantly elevated ox-
LDL compared to baseline, while controls showed no change (Jorde, et al., 2007). On the 
other hand, Kostic (2009) found elevated ox-LDL concentrations in both type 2 diabetics 
Citation Exercise 
protocol 
Lipid oxidation 
markers 
Time points Results 
Vasankari, et al., 
1997 
31 km run and 
marathon 
LDL- & serum- 
CD 
Immediately pre 
& post 
31 km run- No 
change in LDL- 
CD, ↑ serum-CD. 
Marathon- No 
change in LDL- 
or serum-CD 
Vuorimaa, et al., 
2005 
6 hour walk LDL-CD Immediately pre 
& post 
↓ immediately 
post 
Ginsburg, et al., 
1996 
Ironman 
Triathlon 
Plasma lipids 
susceptibility to 
oxidation 
2 days pre & 15 
mins post 
↓ 15 mins post 
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and age and BMI-matched control subjects following a maximal cycle ergometer test. 
These findings implicate, along with the CHF results from Jorde (2007), that middle aged 
individuals who are overweight or have a disease associated with oxidative stress (CHF, 
type 2 diabetes) are more likely to produce increased ox-LDL following maximal 
exercise. However, maximal exercise tests of relatively short duration (≤ 15 minutes) 
apparently will not generate elevated ox-LDL in individuals who are young or not 
overweight or obese. In contrast, one study found that healthy, sedentary subjects with a 
mean age of 25.0 years had increased susceptibility to in vitro LDL oxidation following a 
cycle ergometer max test. Unfortunately, neither BMI nor percent body fat were 
measured for this investigation (Tozzi-Ciancarelli, Penco, & Di Massimo, 2002). Taken 
together, the information concerning the response of ox-LDL to maximal exercise is not 
fully substantiated. Further research is required to delineate the variables involved in this 
dynamic.  
Other acute exercise protocols and ox-LDL. 
 Other acute exercise studies have investigated LDL oxidation, but employed 
protocols other than long endurance exercise or maximal exercise tests. Eleven male 
professional soccer players performed treadmill exercise at 6km/hr (3.6 mi/hr) with 
increases of 2km/hr (1.2 mi/hr) every 3 minutes with a 1 minute rest between 
stages(Klapcinska, et al., 2005).The athletes performed this protocol until volitional 
exhaustion and displayed no significant changes in ox-LDL antibodies. Unfortunately, 
exercise intensity was not measured and exercise duration was not reported. However, 
one might infer that the exercise duration was relatively short and the exercise intensity 
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Table 3. Summary of Maximal Exercise Tests and Ox-LDL Studies 
Citation Exercise 
protocol 
Lipid oxidation 
markers 
Time points Results 
Hsu, et al., 
2000 
Treadmill LDL associated 
lipid peroxides 
Pre, peak & 10 
mins post 
↑ 10 mins 
post 
 J. S. Wang & 
Chow, 2004 
Cycle 
ergometer 
Ox-LDL 
concentration 
Immediately 
pre & post 
No change 
Jorde, et al., 
2007 
Treadmill Ox-LDL 
concentration 
Immediately 
pre & post 
CHF patients  
–↑ 
immediately 
post, controls 
– no change 
Kostic, et al., 
2007 
Cycle 
ergometer 
Ox-LDL 
concentration 
Immediately 
pre & post 
↑in type 2 
diabetics and 
BMI-
matched 
controls 
immediately 
post 
Tozzi-
Ciancarelli, et 
al., 2002 
Cycle 
ergometer 
LDL 
susceptibility to 
oxidation 
Immediately 
pre & post 
↑ 
immediately 
post 
Summary of Maximal Exercise Tests and Ox-LDL Studies. LDL- low density lipoprotein, ox-LDL- oxidized 
low density lipoprotein, ↑- significant increase, ↓- significant decrease. 
 
 
was very high, similar to a VO2 max test. The flat results were also similar to other VO2 
max studies involving young individuals, with others showing no change in ox-LDL 
measures immediately after exercise (Jorde, et al., 2007; J. S. Wang & Chow, 2004).  
Tozzi-Ciancarelliet al. (2002) examined LDL susceptibility to in vitro oxidation 
following 30 minutes of cycle ergometer exercise at 60% VO2 max. Volunteers were 15 
healthy, sedentary males with a mean age of 25.0 years. The investigators found no 
change in LDL lag time immediately post- and 24 hours post-exercise. This study 
reported no control of intake of antioxidants through supplement or diet. In another study, 
 
43 
Type 2 diabetes mellitus patients and age, gender, and BMI matched controls exercised 
for 40 minutes at 70-80% VO2 peak on a cycle ergometer at the beginning and after 
training for 18 weeks (Iborra, et al., 2008).  Ox-LDL concentration showed no difference 
before or after the acute bout either before or after training in patients or controls. 
Measurements were taken immediately before exercise as well as 40 minutes and 24 
hours after the exercise session. Diet and supplement information was not measured. 
However, another study found a significant change in LDL susceptibility to oxidation 
immediately after 30 minutes of moderate intensity treadmill work. Wetzstein and 
colleagues (1998) exercised 12 sedentary individuals and 11 exercise trained individuals 
at 55% and 70% VO2 peak, respectively, which represented a relative moderate intensity 
for each group. There was a similar decrease in ox-LDL lag time in both sedentary (105.3 
± 21.6 vs. 101.8 ± 23.5 min; p = NS) and trained individuals (86.0 ± 22.0 vs. 81.6 ± 18.8; 
p = NS), however only the total group was statistically significant (96.1 ± 23.5 vs. 92.1 ± 
23.3 min; p≤ .03).Nonetheless, this study showed that 30 minutes of exercise has the 
potential to change LDL susceptibility to in vitro oxidation in young individuals. Subjects 
were not taking vitamin/mineral supplements, but diet before the exercise was not 
otherwise controlled. Tomás et al.(2002)measured ox-LDL via ELISA in 17 young, 
healthy men and women in response to acute exercise before and after 16 weeks of 
aerobic training. In the acute exercise sessions the subjects exercised for 30 minutes at 
the work rate achieved at ventilatory threshold (VT). After training, ox-LDL 
concentration was elevated for two hours after exercise, with the concentration peaking 
immediately post-exercise. Conversely, no significant change in ox-LDL occurred in 
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response to acute exercise before training. VO2max and VT where reassessed at week 15 
with significant increases in both fitness variables. The change in ox-LDL concentration 
following acute exercise could be due to the higher absolute workload achieved by the 
participants after training. Subjects were asked to adhere to the same diet in the 3 days 
before the exercise on both occasions. Additionally, no subjects were taking antioxidant 
supplements. Overall, research supports the contention that moderate to high intensity 
exercise for 30 minutes can produce a significant increase in circulating ox-LDL 
immediately following exercise in young healthy subjects.  
Acute exercise and protein carbonyl concentration. 
 Protein oxidation is also a documented consequence of oxidative stress derived 
from acute aerobic exercise. Circulating protein carbonyl (PC) concentration is one 
marker commonly used to measure the degree of oxidative stress induced by physical 
work. Exercise studies have demonstrated that an exercise bout ranging from 30 to 120 
minutes (Bloomer, Davis, Consitt, & Wideman, 2007; Bloomer, Goldfarb, & McKenzie, 
2006; Goldfarb, Patrick, Bryer, & You, 2005) at intensities ranging from 70 to 
80%VO2max (Bloomer, et al., 2007; Bloomer, et al., 2006; Goldfarb, et al., 2005) can 
significantly elevate PCs. Altered PC status has been measured immediately following 
exercise (Alessio, et al., 2000; Bloomer, et al., 2006; Goldfarb, et al., 2005) and up to 10 
hours following more than 45 minutes of exhaustive running (Michailidis, et al., 2007). 
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Table 4. Summary of Other Acute Exercise Protocols and Ox-LDL Studies 
Citation Exercise 
protocol 
Lipid oxidation 
markers 
Time points Results 
Klapcinska, et 
al., 2005 
Progressive 
treadmill run 
with 1 min rest 
between stages 
Ox-LDL 
antibodies 
Pre & 3-4 mins 
post exercise 
No change 
Tozzi-
Ciancarelli, et 
al., 2002 
30 mins of 
cycle ergometer 
exercise at 60% 
VO2 max 
LDL 
susceptibility to 
oxidation 
Immediately 
pre and 
immediately & 
24 hrs post 
No change 
Iborra, et al., 
2008 
40 mins at 70-
80% VO2 peak 
on a cycle 
ergometer 
Ox-LDL 
concentration 
Immediately 
pre and 40 mins 
& 24 hrs post 
No change 
Wetzstein, et 
al., 1998 
30 mins 
treadmill 55% 
(untrained) and 
70% (trained) 
VO2peak 
LDL 
susceptibility to 
oxidation 
Immediately 
pre & post 
No change in 
individual 
groups, ↑ in 
combined 
group 
Tomas, et al., 
2002 
30 mins of 
cycle ergometer 
at maximal 
aerobic power 
output 
Ox-LDL 
concentration 
Immediately 
pre and 
immediately, 
30 mins, 1 hr, 2 
hrs, & 24 hrs 
post 
↑ 
immediately, 
1 hr & 2hrs 
post in 
trained 
subjects 
 
Summary of Other Acute Exercise Protocols and Ox-LDL Studies. LDL- low density lipoprotein, ox-LDL- 
oxidized low density lipoprotein, ↑- significant increase, ↓- significant decrease. 
 
 
Exercise and PON1and Total Antioxidant Capacity 
 
 PON1 response to exercise training. 
 
Investigations examining the PON1 activity response to aerobic exercise training 
have produced mixed results. The inconsistent results can be attributed to the 
inconsistency of the subject characteristics, exercise intervention, and possibly 
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measurement techniques. In essence, these studies provide no clear picture of the PON1 
reaction to an exercise stimulus. 
 After 16 weeks of aerobic training 5 days per week for 50 minutes, Tomas et al. 
(2002) found no change in PON1 activity in young males and females. In a case-control 
study, there was no difference in PON1 levels between triathletes and controls (Brites, et 
al., 2006). Even with diet and exercise induced weight loss, PON1 activity and 
concentration decreased (Rector, et al., 2007) or was unaltered (Roberts, Ng, Hama, 
Eliseo, & Barnard, 2006) in overweight and obese patients. Individuals with type 2 
diabetes, which is associated with low PON1 activity, produced no change in PON1 after 
18 weeks of exercise training (Iborra, et al., 2008). Richter et al. (2005) investigated the 
effect of 12 weeks of exercise training with individuals at elevated risk or having CVD. 
They demonstrated that the exercise treatment had no influence on PON1 activity. 
Conversely, individuals with ischemic heart disease exercised for 12 weeks, which 
produced a 16.7% increase in PON1 activity (Goldhammer, et al., 2007). As stated 
previously, individuals with CVD typically associate with low PON1 activity compared 
to control subjects. So in this case, exercise was able to restore PON1 activity to a 
“normal” level. In another study, individuals with metabolic syndrome exercised at a 
moderate intensity for 3 months. After the training period PON1 activity increased 
significantly despite no observed change in HDL concentration (Casella-Filho, et al., 
2011). A case control study of male and female adolescents found that adolescent 
basketball players had significantly higher PON1 activity (paraoxonase and arylesterase) 
than sedentary controls (Cakmak, Zeyrek, Atas, & Erel, 2010). Similarly, another study 
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investigated the PON1 activity (paraoxonase) of adolescent wrestlers (n=18) compared to 
sedentary controls (n=18). They found PON1 activity to be significantly higher in the 
wrestlers (Hamurcu, Saritas, Baskol, & Akpinar, 2010).Taken together, the research 
concerning the reaction of PON1 activity to aerobic exercise training is inconclusive.  
PON1 response to acute exercise. 
 
 Investigations measuring PON1 activity before and after an isolated bout of 
exercise are scarce. Similar to exercise training results, the reaction of PON1 to acute 
exercise has varied. Exercise protocol, blood sample time points, measurement substrate, 
and subject characteristics could contribute to the inconsistent results. 
 Eleven marathon and ultra-marathon trained males ran a mean distance of 47.8 
km (28.68 mi) in 4 hours. Blood was drawn immediately before and immediately after 
the run. PON1 activity was measured with no significant difference between pre and post 
measures (Benitez, et al., 2002). This study could indicate that a relatively long exercise 
bout is incapable of eliciting a PON1 response, at least in trained individuals. In another 
study, 10 young basketball players trained two or three times per week for 30 days. 
Training sessions consisted of approximately 90 minutes of basketball training. In 
addition, the players supplemented alpha-tocopherol during the 30-day training period. 
PON1 activity significantly decreased immediately after “practice” both before and after 
training, but alpha-tocopherol supplementation blunted the response (Tsakiris, et al., 
2009). The physical activity protocol in this study was poorly controlled, leading to 
speculation about the exact physiological stimulus; intensity was not measured and the 
frequency was loosely described. Similarly, PON1 activity was assessed in adolescent 
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Table 5.Summary PON1 Activity Response to Chronic Exercise 
Citation Exercise 
protocol 
Substrate Results 
Tomas, et al., 
2002 
16 weeks, 5 
days/wk, 50 
mins 
Paraoxon No change 
Brites, et al., 
2006 
Triathletes vs. 
controls 
Paraoxon and 
phenylacetate 
No difference 
Roberts, Ng, 
Hama, Eliseo, 
& Barnard, 
2006 
3 weeks, 7 
days/wk, 45-60 
mins, 70-85% 
max HR 
Paraoxon No change 
Iborra, et al., 
2008 
18 weeks, 3 
days/wk, 40 
mins, 70-80% 
VO2 peak 
Phenylacetate No change 
Rictor, et al., 
2005 
12 weeks, 3-5 
days/wk, 30-60 
mins, 60% 
HRR 
Phenylacetate No change 
Goldhammer, 
et al., 2007 
12 weeks, 1 
day/wk, 45 
mins, 70-85% 
HR max. 
2 day/wk, 30 
mins 
calisthenics  
Phenylacetate Increase 
Casella-Filho, 
et al., 2011 
3 months, 3 
days/wk, 45 
mins, moderate 
intensity  
Paraoxon Increase 
Cakmak, 
Zeyrek, Atas, 
&Erel, 2010 
adolescent 
basketball 
players vs. 
controls 
Paraoxon and 
phenylacetate 
Higher in 
athletes 
Hamurcu, 
Saritas, Baskol, 
&Akpinar, 
2010 
Adolescent 
wrestlers vs. 
controls 
Paraoxon Higher in 
athletes 
 
Summary PON1 Activity Response to Chronic Exercise. PON1- Paraoxonase 1,  
↑- significant increase, ↓- significant decrease. 
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wrestlers before and immediately after 1.5 hours of wrestling training. The researchers 
found PON1 activity to be unaltered following the physical activity (Hamurcu, et al., 
2010).  
Type 2 diabetes mellitus patients and control subjects matched for age, gender, 
and BMI exercised for 40 minutes at 70-80% VO2 peak on a cycle ergometer before and 
after 18 weeks of exercise training. PON1 activity showed no difference before or after 
the acute bout either before or after training in patients or controls. Measurements were 
taken immediately before exercise as well as 40 minutes and 24 hours after the exercise 
session (Iborra, et al., 2008). On the other hand, Tomas et al. (2002) found that PON1 
activity increased after 30 minutes of intense cycling. PON1 activity was measured 
immediately before and after an acute bout of exercise before and after 16 weeks of 
supervised, aerobic training. Young, healthy volunteers cycled at their maximal aerobic 
power output for 30 minutes before and after the 16 weeks of training. Following 
training, but not before, PON1 activity was significantly higher than baseline 
immediately after exercise, with values returning to baseline by 30 minutes post-exercise. 
PON1 activity was measured before, immediately after, and two hours after a treadmill 
maximal exercise test in young, fit men (Otocka-Kmiecik, et al., 2010). They found a 
significant increase in PON1 activity immediately after the exercise with a return to 
baseline by 2 hours post-exercise.  
 To summarize, the PON1 response to an acute exercise bout has been examined in 
six studies. Investigations have found no effect (Benitez, et al., 2002; Hamurcu, et al., 
2010; Iborra, et al., 2008), an increase (Otocka-Kmiecik, et al., 2010; Tomas, et al., 
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2002), and a decrease (Tsakiris, et al., 2009) in PON1 activity following a single exercise 
session. Benitez et al. (2002) and Tsakiriset al. (2009) failed to report exercise intensity, 
making results difficult to interpret. Iborra et al.(2008) reported no change in ox-LDL or 
PON1 following 40 minutes of exercise at 70-80% VO2 peak on a cycle ergometer. 
Unfortunately, blood was not drawn immediately following exercise, but 40 minutes and 
24 hours after, possibly missing an alteration in PON1 activity. Tomás et al.(2002), as 
mentioned previously, reported a peak in ox-LDL immediately following 30 minutes of 
vigorous cycling in trained individuals. In this study elevated PON1 activity was also 
reported immediately after exercise. These results give rise to the specific aims of the 
proposed study, as they demonstrate that ox-LDL and PON1 can increase concurrently 
immediately following an exercise session. Unfortunately, no study has attempted to 
measure the association between alterations of ox-LDL concentration and PON1 activity 
after an isolated exercise bout. Furthermore, a dose-response relationship between ox-
LDL and PON1 across exercise intensities (representing differing levels of oxidative 
stress) has not been examined.   
Total antioxidant capacity. 
 
 Several enzymes, vitamins and reducing molecules comprise the complex 
antioxidant system within the blood. These substances work in concert to protect the 
body from the harmful effects of ROS. Because of the difficulty in measuring each 
component of the antioxidant system separately, methods have been developed to assess 
the total antioxidant capacity (TAC) of the serum or plasma. As a result of oxidative 
 
51 
Table 6. Summary PON1 Activity Response to Acute Exercise 
Citation Exercise 
protocol 
Time points Substrate Results 
Benitez, et al., 
2002 
4 hr run Immediately 
pre & 
immediately 
post 
Phenylacetate No change 
Tsakiris, et al., 
2009 
Basketball 
training, 90 
mins 
Immediately 
pre & 
immediately 
post, before and 
after training 
Paraoxon and 
phenylacetate 
Both ↓ 
immediately 
post, before 
and after 
training 
Iborra, et al., 
2008 
40 mins at 70-
80% VO2 peak 
on a cycle 
ergometer 
Immediately 
pre and 40 
minutes & 24 
hrs post 
Phenylacetate No change 
Tomas, et al., 
2002 
30 mins at 
maximal 
aerobic power 
output on a 
cycle ergometer 
Immediately 
pre & 
immediately 
post, before and 
after training 
Paraoxon ↑ 
immediately 
post after 16 
wks of 
training. 
No change 
before 
training 
Otocka-
Kmiecik, et al., 
2011 
Treadmill max 
exercise 
Immediately 
pre, 
immediately 
post& 2 hr post 
Paraoxon and 
phenylacetate 
Both ↑ 
immediately 
post 
Hamurcu, 
Saritas, Baskol, 
&Akpinar, 
2010 
1.5 hours of 
wrestling 
training 
Immediately 
pre & 
immediately 
post 
Paraoxon No change 
 
Summary PON1 Activity Response to Acute Exercise. PON1- Paraoxonase 1, ↑- significant increase, ↓- 
significant decrease. 
 
 
stress induced by exercise, the antioxidant components of the blood are temporarily 
diminished in order to reduce free radicals. Thus, the detriment of TAC in response to 
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exercise can be used as a measure of oxidative stress. Reduced TAC has been observed 
following a maximal incremental exercise test (Steinberg, Delliaux, & Jammes, 2006). 
TAC did not change in response to 30 minutes of treadmill running at 60% VO2max, but 
was significantly diminished immediately following nearly 40 minutes of exhaustive 
running (T. A. Watson, et al., 2005). There was no change in TAC immediately after 30 
minutes of cycle ergometery, however TAC significantly decreased immediately 
following a cycle ergometer VO2max test (Tozzi-Ciancarelli, et al., 2002). It appears that 
TAC can drop in response to relatively short, intense exercise, but intensities at 60% 
maximal capacity have been incapable of eliciting a change in TAC. This provides 
evidence that exercise intensity (level of oxidative stress) is reflected by the change in 
TAC immediately following exercise.  
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CHAPTER III 
METHODS 
 
 
Overview 
 
In this study, 15 aerobically trained men (n=12) and women (n=3) aged 18-35 
participated in a fitness assessment and two different exercise treatments. The fitness 
assessment was conducted to determine the subjects’ maximal oxygen consumption (VO2 
max). In the two subsequent exercise treatments, subjects exercised on a treadmill for 30 
minutes at 60% and 80% VO2 max. Exercise-induced oxidative stress has been shown to 
be intensity dependent (Goto, et al., 2007), therefore the exercise treatments were 
expected to significantly alter blood concentrations of ox-LDL and PON1in a dose-
dependent manner. The fitness assessment test and each of the two treatments were 
separated by at least one week. Treatment order was randomly counterbalanced. Blood 
was drawn immediately before (PRE), immediately after (0 POST), and 15 minutes after 
(15 POST) each exercise session. As in other studies (Tomas, et al., 2002; Wetzstein, et 
al., 1998), changes in ox-LDL and PON1 were expected to be at their peak immediately 
following exercise. However, as a safeguard, a second blood collection occurred at 15 
minutes post-exercise in case the peak increase in either was delayed. Schematics 
detailing the timing of exercise treatments and blood collections are presented in Figures 
2 and 3, respectively.
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Figure 2. Timeline for Exercise Treatments 
             
 
 
             
 
 
 
 
Figure 3. Timeline for Blood Collections (BC) during Each Exercise Treatment 
             
 
  BC Exercise       BC              BC       
  PRE  Treatment    0 POST       15 POST      
             
 
Subject Recruitment/Selection 
Exercise-trained volunteers were recruited primarily through flyers, campus 
publications, classroom announcements, and announcements sent to local fitness and 
running clubs. Exclusion criteria included history of cardiovascular disease, diabetes 
mellitus, dyslipidemia, physical disability, and chronic respiratory disease. Other 
exclusion criteria included resting blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), regular consumption of >2 alcoholic drinks per day, tobacco use, oral birth 
control use, regular vitamin or mineral supplementation within the past 2 months, and 
anti-inflammatory medication usage. Subjects who used anti-inflammatory treatment for 
acute illness were delayed by one week after discontinuation of the medication. 
Exercise 
Treatment 
VO2 max Test 
≥  one 
week 
  
 
≥  one 
week 
  
 
Exercise 
Treatment 
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Individuals aged 18-35 years who performed ≥90 minutes of exercise per week at 6 or 
above on the 10-point Borg scale (Borg, 1998)for the past 3 months were eligible to 
participate in this study. Trained individuals were utilized because Tomás et al. (2002) 
found greater ox-LDL and PON1 responses in the trained state versus the untrained state. 
Participants also were required to have a body mass index (BMI) < 25 kg/m2 or percent 
body fat < 20% for males or <25% for females. Criteria for participation were designed 
to enhance homogeneity of the cohort and control for variables that could affect 
lipoprotein metabolism and antioxidant status.   
 
Fitness Assessment 
Participants exercised to volitional fatigue using a horizontal treadmill (General 
Electric Medical Systems, Case version 6.5) running protocol. Individuals began at a 
pace of 120 m/min (4.5 mph) with speed increasing 10 m/min (0.3-0.4 mph) every 
minute until a heart rate of 120 beats per minute was achieved. From there, speed was 
increased 10 m/min (0.3-0.4 mph) every three minutes until volitional fatigue. Volume of 
oxygen consumption (VO2) was analyzed breath-by-breath via an automated metabolic 
system (Parvo Medic TrueOne 2400, Sandy, UT). Criteria for achievement of maximum 
oxygen consumption (VO2max) included the following: attainment of ≥ 95% age predicted 
maximal heart rate (220-age), respiratory exchange ratio (RER) of ≥ 1.15, or failure of 
VO2 to increase ≥2 mL⋅kg-1⋅min-1 in the final minute of exercise. The three highest 
consecutive 20-second VO2 values were averaged to determine VO2max. During this 
assessment ventilatory threshold (VT) was identified as the point at which ventilation 
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increased disproportionally compared to the increase ofVO2. Body fat percentage was 
evaluated via a seven-site skinfold test using Harpenden calipers (Creative Health 
Products, Ann Arbor, MI). Sex-specific equations were used to determine body fat 
percentage (Jackson & Pollock, 1978; Jackson, Pollock, & Ward, 1980). 
 
Blood Collection and Analysis 
Wetzstein et al.(1998) demonstrated a significant increase in LDL susceptibility 
to oxidation immediately following exercise. Tomas et al.(2002) measured ox-LDL 
concentration at several time points following exercise and found that it peaked 
immediately afterward. PON1 activity also peaked immediately after exercise and 
returned to baseline by 30 minutes post exercise. The first post-exercise PON1 
measurement by Iborra et al.(2008) was at the 40 minute time point and displayed no 
change from baseline, possibly missing the exercise-induced change in PON1 activity. 
Therefore, for this investigation blood was collected PRE, 0 POST and 15 POST with 
each treatment session. These collection time points were chosen in an attempt to 
measure ox-LDL concentration and PON1 activity at their peak elevations and 
subsequent decline. Subjects were allowed to drink water ad libitum between 0 POST and 
15 POST. Table 7 summarizes the blood collections and the associated blood markers.  
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Table 7. Blood Collections and Associated Measurement Variable 
 PRE 0 POST 15 POST 
Oxidized low-
density lipoprotein 
(Ox-LDL) 
X X X 
Paraoxonase 1 
(PON1) 
X X X 
Protein Carbonyl 
(PC) 
X X 
 
Total Antioxidant 
Capacity (TAC) 
X X 
 
Total cholesterol, triglyceride, LDL, and HDL concentrations were determined at 
baseline (the PRE time point associated with the first exercise treatment).  
 
After a 12-hour fast, approximately 30 ml of blood was collected from an 
antecubital vein by a trained technician at each time point (PRE, 0 POST and 15 POST). 
Due to its effect on lipoprotein metabolism, participants were required to refrain from 
drinking alcohol for 48 hours prior to each exercise session. Blood for plasma 
measurements was collected into vacutainers containing EDTA and centrifuged 
immediately. Blood for serum measurements was collected into vacutainers with no 
additive and were allowed to clot at room temperature for 30 minutes before 
centrifugation. All samples were centrifuged in a Beckman Coulter (Allegra 6KR) 
centrifuge (Palo Alto, CA) at 1,500 rpm for 20 minutes at 4oC. After centrifugation, 
plasma and serum were aliquotted and stored at -80°C. 
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Measurement of ox-LDL concentration. 
Ox-LDL concentration was measured in plasma using a competitive enzyme-
linked immunosorbent assay (ELISA) (Mercodia AB, Uppsala, Sweden).Absorbance was 
analyzed with a Bio-Tek microplate reader (Powerwave 340, Winooski, VT) at 450 nm. 
Ox-LDL was determined at PRE, 0 POST, and 15 POST. Before centrifugation small 
portions of whole blood were used to measure hemoglobin (Drabkin, 1948) and 
hematocrit (Dill & Costill, 1974). Based on these values, post-exercise ox-LDL 
concentrations were adjusted for plasma volume changes (Greenleaf, Convertino, & 
Mangseth, 1979).  
Measurement of PON1 activity. 
The activity of PON1 was measured in serum using the spectrophotometric 
OXItek Arylesterase/Paraoxonase Assay kit from the ZeptoMetrix Corporation (Buffalo, 
NY). This assay measures phenol formation at an absorbance of 270 nm at 25˚C, pH of 
8.0. The rate of phenylacetate hydrolysis was monitored for 1 minute using a Shimadzu 
UV 1800 spectrophotometer (Kyoto, Japan). The activity of PON1 was determined at 
PRE, 0 POST, and 15 POST.  
Measurement of total antioxidant capacity. 
The measurement of total antioxidant capacity (TAC) was performed at the PRE 
and 0 POST time points associated with each exercise treatment to quantify the 
antioxidant environment of the blood before and after exercise. TAC was measured in 
serum with the Antioxidant Assay Kit from Cayman Chemicals (Ann Arbor, MI). This 
assay determined antioxidant capacity by measuring the ability of the serum to inhibit the 
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oxidation of 2,2’-Azino-di-[3-ethylbenzthiazoline sulphonate](ABTS) by metmyoglobin. 
The ability of the serum antioxidants to inhibit the oxidation of ABTS was compared to 
Trolox, a water soluble antioxidant, which provided results in mM of Trolox equivalents. 
The suppression of absorbance was analyzed with a Bio-Tek microplate reader 
(Powerwave 340, Winooski, VT) at 750 nm. 
Measurement of protein carbonyl concentration. 
Protein carbonyl (PC) assessment was used as a general oxidative stress marker 
and was also measured at time points PRE and 0 POST. PC concentration was assessed in 
plasma using an ELISA kit from BioCell Corporation (San Diego, CA). In this assay, 
absorbance was analyzed with a Bio-Tek microplate reader (Powerwave 340, Winooski, 
VT) at 450 nm. 
Measurement of blood lipid profile. 
Total cholesterol (TC), high density lipoprotein (HDL), and triglyceride (TG) 
concentrations were analyzed using commercialized assays from Wako Chemicals USA 
Inc. (Richmond, VA). Low density lipoprotein (LDL) concentration was estimated using 
the Friedewald formula [TC-HDL-(TG/5)] (Friedewald, Levy, & Fredrickson, 1972).  
Baseline LDL and HDL were assessed at the PRE time points. These measures were used 
for descriptive purposes and to assess if changes in ox-LDL and PON1 were related to 
baseline LDL and HDL concentrations, respectively.  
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Control of Diet and Extracurricular Physical Activity 
To control for dietary influence on blood variables, 72 hour dietary food logs 
were collected from each participant listing all foods eaten in that timeframe before each 
treatment. Participants retained copies of the food logs and were instructed to consume 
the same diet in the 3 days prior to each exercise treatment. Participants were also 
instructed to refrain from consumption of alcoholic beverages for 48 hours before each 
blood collection.  
The dietary logs were used to ensure that relevant macro- and micro-nutrient 
intake did not differ significantly in the days before each exercise treatment. Fat, 
carbohydrate, and protein intake were evaluated as well as exogenous antioxidant intake 
of α-tocopherol, ascorbic acid, and β-carotene (Diet Analysis Plus, Wadsworth 
Publishing Co., Salem, OR).   
In order to prevent a detraining effect, the participants were instructed to exercise 
according to their regular routines in the time period between the fitness assessment and 
the exercise treatments. However, to prevent carry-over effects, the subjects were 
instructed to refrain from regular exercise 48 hours before the next laboratory exercise 
treatment. To assess a possible between-treatment difference in physical activity over the 
week leading up to each exercise treatment, the subjects completed the Kuopio Ischemic 
Heart Disease Study (KIHD) Seven-Day Physical Activity Recall (Lakka & Salonen, 
1987) immediately before each exercise treatment.  
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Data Analysis 
Specific aim #1: Investigate the effect of acute exercise on ox-LDL concentration in 
response to two acute exercise treatments of different intensities. 
A 2 (treatment) x 3 (time) repeated measures ANOVA was utilized to assess differences 
in ox-LDL concentration between the treatments across the time points PRE, 0 POST, 
and 15 POST.  Tukey’s honestly significant difference test evaluated the significance of 
pairwise cell contrasts.  
Specific aim #2: Investigate the effect of acute exercise on PON1 activity in response to 
two acute exercise treatments of different intensities. 
A (treatment) x 3 (time)repeated measures ANOVA was utilized to assess differences in 
PON1 activity between the treatments across the time points PRE, 0 POST, and 15 
POST. Tukey’s honestly significant difference test evaluated the significance of pairwise 
cell contrasts. 
Specific aim #3: Examine the relationship between changes in ox-LDL concentration 
and PON1 activity in response to acute exercise. 
A Pearson product moment correlation with Bonferroni’s correction for multiple 
comparisons was utilized to assess the relationship between changes in PON1 activity 
and ox-LDL concentration within each exercise treatment.  
In addition, other analyses indirectly associated with the specific aims were 
performed. Two (treatment) by two (time) repeated measures ANOVA assessed if 
differences existed in both TAC and PC concentrations between and within the exercise 
treatments at the PRE and 0 POST time points. To assess if relationships existed between 
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baseline LDL and change in ox-LDL, and between baseline HDL and PON1 change, 
Pearson product moment correlations were performed. A repeated measures ANOVA 
assessed if significant differences in fat, carbohydrate, protein, α-tocopherol, ascorbic 
acid, and β-carotene intake existed between the exercise treatments. Finally, a paired t-
test was performed to assess any differences in physical activity in the week prior to each 
exercise treatment. Statistical analyses were performed using the Statistical Package for 
the Social Sciences version 15.1 (SPSS 15.1) with statistical significance for all analyses 
set at p ≤ 0.05. 
 
Power and Sample Size Justification 
This investigation employed 2 x 3 repeated measures ANOVA to assess the 
differences in the two exercise treatments with three blood draws associated with each 
treatment. A moderate effect size of 0.5 was estimated and a power level ≥ 0.80was 
required for statistical significance. This information was entered into G*Power (Franz 
Faul, Universität Kiel, Germany) which calculated that a total sample size of 14 subjects 
was required to meet the estimated effect size of 0.5 with a power ≥ 0.80. 
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CHAPTER IV 
RESULTS 
 
 
Participant Characteristics 
 Fifteen volunteers met study requirements and successfully completed all data 
collection procedures. Descriptive characteristics are presented in Table 8. Twelve 
Caucasian males and three Caucasian females participated, with significant differences 
between sexes existing for height, weight, body mass index, body fat percentage, fat 
mass, and fat-free mass. The subjects who volunteered for this study were young, fit, and 
displayed several healthy cardiovascular disease profiles. The mean blood lipid values 
fell within the healthy ranges for total cholesterol (161.0 mg⋅dl-1), LDL-C (91.8 mg⋅dl-1), 
HDL-C (54.6 mg⋅dl-1), and triglycerides (72.5 mg⋅dl-1) (ATP-III, 2001). In addition, BMI 
(22.9 kg⋅m-2) and body fat percentage (9.6%, males; 21.1% females) identified the 
subjects as free of excessive body weight and fat. The mean cardiorespiratory fitness was 
56.1 ml⋅kg-1⋅min-1 (90th percentile)and 49.5ml⋅kg-1⋅min-1 (90th percentile) for males and 
females, respectively (ACSM, 2010). This elevated level of fitness was also represented 
in the high amount of weekly physical activity reported by the participants (7093.4 
kcal⋅wk-1). Resting blood pressure was also healthy with average measurements of 120.5 
mm Hg and 65.9 mm Hg for systolic and diastolic, respectively (Chobanian, et al., 2003). 
Unexpectedly, although a trend existed, VO2max was not significantly higher in men than 
in women. There were also no significant between-sex differences in plasma lipids. 
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Table 8. Descriptive Characteristics 
 Overall 
(n= 15) 
Males  
(n=12) 
Females 
(n=3) 
Age (years) 26.3 ± 1.2 25.8 ± 1.4 28.3 ± 1.2 
Height (m) 1.76 ± 0.02 1.79 ±  0.02 1.65 ± 0.02 † 
Weight (kg) 71.1 ± 2.6 74.7 ± 2.0 56.4 ± 4.7 † 
BMI (kg⋅m-2) 22.9 ± 0.5 23.4 ± 0.4 20.7 ± 1.4 * 
Body fat (%) 11.9 ± 1.5 9.6 ± 0.9 21.1 ±  2.0 ‡ 
Fat mass (kg) 8.2 ± 0.9 7.3 ± 0.8 12.1 ± 2.2 * 
Fat-free mass (kg) 62.8 ± 2.8 67.4 ± 1.7 44.3 ± 2.5 ‡ 
VO2max 
(ml⋅kg-1⋅min-1) 54.8 ± 1.7 56.1 ± 1.9 49.5 ±  2.5 
TC (mg⋅dl-1) 161.0 ± 7.5 162.5 ± 7.0 154.9 ± 29.3 
HDL-C (mg⋅dl-1) 54.6 ± 2.7 55.4 ± 3.1 51.8 ± 5.3 
LDL-C (mg⋅dl-1) 91.8 ± 6.4 92.7 ± 6.2 88.3 ±  23.9 
TG (mg⋅dl-1) 72.8 ± 7.3 72.5 ± 9.1 74.1 ±  5.1 
TC⋅HDL-C-1 2.9 ± 0.1 3.0 ± 0.2 3.0 ±  0.3 
Ox-LDL (U⋅L-1) 40.5 ± 2.5 40.8 ± 2.7 38.9 ± 8.0 
PON1 activity (kU⋅L-1) 156.9 ± 9.3 155.5 ± 11.0 162.5 ± 19.3 
Systolic BP (mm Hg) 120.5 ± 2.8 123.0 ± 3.1 110.3 ± 1.8 
Diastolic BP (mm Hg) 65.9 ± 1.3 65.9 ± 1.6 66.0 ± 2.1 
Leisure Time Physical 
Activity (kcal⋅wk-1) 
7093.4 ±  
1458.2 7812.8 ± 1774.0 4215.9 ± 73.6 
 
Values are mean ±SEM. BMI, body mass index; TC, total cholesterol, HDL-C, HDL 
cholesterol; LDL-C, LDL cholesterol; TG, triglycerides; BP, blood pressure. Different across 
gender (*p<.05; †p<.01; ‡p<.001). 
 
 
 Previous research has demonstrated a significant correlation between LDL- C and 
ox-LDL concentration (Toshima, et al., 2000). This phenomenon was also consistent 
within the present study. A Pearson Product Moment correlation of 0.82 was calculated at 
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a significance of p < 0.001 for baseline LDL-C and baseline ox-LDL concentrations 
(Figure 4.) 
 
Figure 4.Correlation between Baseline LDL-C and Baseline Ox-LDL Concentration. 
 
 
 Despite the fact that HDL is an important carrier for PON1, previous 
investigations have reported a weak or no relationship between HDL concentration and 
PON1 activity (Boesch-Saadatmandi, et al., 2010; Roest, et al., 2007; Tomas, et al., 
2002). This was the case in the current study, as no relationship was found between the 
baseline concentration of HDL-C and PON1 activity (r = 0.029, p = 0.918) (Figure 5).  
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Figure 5.Correlation between Baseline HDL-C and Baseline PON1 Activity 
 
Exercise Treatments 
 Participants performed 30 minutes of treadmill running at 60% and 80% in 
random order with 1 week between treatment sessions. The 60% session was performed 
at an average of 59.7% VO2max   and the 80% session was performed at 79.2%VO2max. 
Other mean characteristics of the treatment sessions are displayed in Table 9. 
 
Physical Activity and Diet Prior to Exercise Treatments 
 Paired t-tests revealed no significant differences between leisure-time physical 
activity and macronutrient and antioxidant vitamin intake in the days prior to either 
exercise treatment session (Table 10).  
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Table 9. Performance Data during Exercise Sessions 
 60 % session 80% session p  value 
%VO2max 59.7±0.6 79.2 ± 0.7 ≤0.001 
VO2(ml·kg-1·min-1) 32.7 ± 0.9 43.4 ± 1.3 ≤0.001 
Energy expenditure 
(kcal) 
348.6 ± 16.7 464.7 ± 24.4 ≤0.001 
Kcal/kg 4.9 ± 0.1 6.5 ± 0.2 ≤0.001 
RER 0.88 ± 0.01 0.93 ± 0.01 ≤0.001 
VE(L/min) 56.4 ± 2.7 85.9 ± 5.6 ≤0.001 
HR (bpm) 139.4 ± 2.2 169.6± 2.9 ≤0.001 
RPE (6-20 scale) 11.0 ± 0.5 14.1 ± 0.6 ≤0.001 
 
Values are mean ± SEM. RER, respiratory exchange ratio; RPE, rating of perceived 
exertion; VE, minute Ventilation; HR, heart rate. 
 
 
Plasma Volume Changes 
 Hematocrit and hemoglobin measurements were utilized to assess changes in 
plasma volume in response to the exercise treatments (Greenleaf, et al., 1979). Pre and 
post exercise hematocrit, hemoglobin and calculated plasma volume changes are 
presented in Table 11. Since LDL’s large lipid content prevents it from freely traversing 
the vascular endothelium, ox-LDL values have been corrected for plasma volume shifts 
and are reported in the corrected state. 
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Table 10. Physical Activity and Diet Prior to Exercise Treatments 
 
3-day average 
prior to 60% 
session 
3-day average 
prior to 80% 
session 
p value 
Energy intake (kcal) 2826.0±249.8 2851.5±230.5 0.916 
CHO (%) 53.0±2.8 53.5 ±2.4 0.818 
Fat (%) 30.4 ±2.0 31.5±1.9 0.623 
PRO (%) 15.9±1.4 16.3±1.0 0.786 
Cholesterol (mg) 341.4 ±52.9 384.4±70.8 0.585 
Vitamin C (mg) 122.6 ±20.3 151.2±30.9 0.239 
Vitamin A (μg) 1796.6 ±392.9 2214.0±446.2 0.541 
Vitamin E (mg) 8.2± 2.4 7.4±1.3 0.674 
 
7-day total prior to 
60% session 
7-day total prior to 
80% session  
Leisure Time Physical 
Activity (kcal/wk) 4289.9±750.1 4396.3±890.1 0.865 
 
Values are mean ± SEM. CHO, carbohydrate; PRO, Protein 
 
 
 
 
 
 
69 
Table 11. Plasma Volume Correction Data 
 60% session  80% session 
 PRE 0 POST 15 POST  PRE 0 POST 15 POST 
Hemoglobin (g/dL) 14.5 ± 0.2 14.8 ± 0.3 14.1 ± 0.2  14.7± 0.3 15.2 ± 0.3 14.7 ± 0.3 
Hematocrit (%) 44.6 ± 0.7 44.2 ± 0.8 42.9 ± 0.8  45.2 ± 0.7 45.7± 0.7 44.2 ± 0.7 
Plasma Volume Δ (%) 
 
-1.79 ± 1.2 5.35 ± 2.1  
 
-3.96 ± 1.3 1.97 ± 1.6 
 
Values are mean ± SEM 
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Ox-LDL and PON1 in Response to Acute Exercise 
Specific Aim #1 was to “investigate the effect of acute exercise on ox-LDL 
concentration in response to two acute exercise treatments of different intensities.”A two 
(treatment) by three (time point) repeated measures ANOVA was utilized to assess this 
aim. The between groups test indicated that the treatment variable was not significant (F 
= 0.000, p = 0.993), thus there was a similar response of ox-LDL concentration between 
the 60% exercise treatment and the 80% treatment (Figure 6). Mauchly’s Test of 
Sphericity calculated to be significant, therefore the Huynh-Feldt F-statistic was used to 
assess the within variable of time. The within subjects test resulted in no significant 
difference in ox-LDL concentration across the time points (F = 2.420, p = 0.115), 
indicating that ox-LDL concentration was not significantly augmented in response to 
exercise. Consequently, the interaction of treatment and time point was also not 
significant (F = 0.456, p = 0.580). In addition, Pearson Product moment correlation found 
no significant relationship between VO2max and changes in ox-LDL concentration at 0 
POST (60%, r = -0.018, p = 0.948; 80%, r = -0.345, p = 0.208) or at 15 POST (60%, r = 
0.025, p = 0.930; 80%, r = -0.191, p = 0.494). Cohen’s d calculation also revealed effect 
sizes of 0.09 and 0.24 for the changes in ox-LDL concentration from PRE to 15 POST for 
the 60% and 80% treatments respectively. The effect sizes indicate a small effect of 
exercise on ox-LDL concentration. 
Specific Aim #2 was to “investigate the effect of acute exercise on PON1 activity 
in response to two acute exercise treatments of different intensities.” A two (treatment) 
by three (time point) repeated measures ANOVA was utilized to assess this aim. The 
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between groups test indicated that the treatment variable was not significant (F = 0.003, p 
= 0.960), thus there was a similar response of PON1 activity between the 60% exercise 
treatment and the 80% treatment (Figure 7). The within subjects test found that there was 
no significant difference in PON1 activity across the time points (F = 2.085, p = 0.134), 
indicating that PON1 activity was not significantly augmented in response to exercise. 
Consequently, the interaction of treatment and time point was also not significant (F = 
.121, p = 0.887). Cohen’s d calculation also revealed effect sizes of 0.05 and 0.12 for the 
changes in PON1 activity from PRE to 15 POST for the 60% and 80% treatments 
respectively. The effect sizes indicate a small effect of exercise on PON1 activity. 
 
Figure 6.Ox-LDL Response to 60% and 80% Treatment Session. Bars indicate SEM. 
 
 
 
PC measurements were analyzed PRE and 0 POST with the 60% and 80% 
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variable was not significant (F = 0.168, p = 0.685), thus there was a similar response of 
PC between the 60% exercise treatment and the 80% treatment. The within subjects test 
found that there was no significant difference in PC across the time points (F = 2.053, p = 
0.163), indicating that PC was not significantly augmented in response to exercise. 
Consequently, the interaction of treatment and time point was also not significant (F 
=2.253, p = 0.145). 
 
Figure 7. PON1 Response to 60% and 80% Treatment Sessions. Bars indicate SEM. 
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TAC measurements were analyzed PRE and 0 POST with the 60% and 80% 
treatment sessions (Table 12). The between groups test indicated that the treatment 
variable was not significant (F = 0.118, p = 0.734), thus there was a similar response of 
TAC between the 60% exercise treatment and the 80% treatment. The within subjects test 
found that there was no significant difference in TAC across the time points (F = 0.437, p 
= 0.514), indicating that TAC was not significantly augmented in response to exercise. 
Consequently, the interaction of treatment and time point was also not significant (F = 
0.572, p = 0.456). 
 
 
 
 The third Aim of this study was to “examine the relationship between changes in 
ox-LDL concentration and PON1 activity in response to acute exercise.” Pearson product 
moment correlation was utilized to assess this aim. The correlation between the change in 
ox-LDL and PON1 from PRE to 0 POST in response to 60% was 0.485 (p = 0.067) 
(Figure 8). The correlation between the change in ox-LDL and PON1 from PRE to 15 
POST in response to 60% was 0.072 (p = 0.798) (Figure 9). The correlation between the 
change in ox-LDL and PON1 from PRE to 0 POST in response to 80% was -0.183 (p = 
0.513) (Figure 10). The correlation between the change in ox-LDL and PON1 from PRE 
Table 12. PC and TAC in Response to Acute Exercise 
 TAC (mM of Trolox eq.)  PC (nmol/mg) 
 60% VO2max 80% VO2max  60% VO2max 80% VO2max 
PRE 1.7 ± 0.1 1.7 ± 0.1  0.25 ± 0.04 0.24 ± 0.04 
0 POST 1.7 ± 0.2 1.8 ± 0.2  0.28 ± 0.04 0.24 ± 0.04 
 
Values are mean ± SEM. PC, protein carbonyls; TAC, total antioxidant capacity.  
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to 15 POST in response to 80% was 0.265 (p = 0.339) (Figure 11). The possibility of a 
time lag between the change in one variable to the change in the other could exist. To 
assess this phenomena, correlations were conducted between the change in ox-LDL at 0 
POST and the change in PON1 at 15 POST in response to 60% (r = 0.266, p = 0.338) and 
80% (r = -0.289, p = 0.297). Likewise correlations were conducted between the change in 
PON1 at 0 POST and the change in ox-LDL at 15 POST in response to 60% (r = 0.167, p 
= 0.551) and 80% (r = -0.036, p = 0.899). No significant relationship was discovered 
between the changes in ox-LDL concentration and PON1 activity in response to either 
the 60% or 80% treatment sessions. Even when converted to percent change, Pearson 
product moment correlation revealed no significant relationship between the changes in 
ox-LDL concentration and PON1 activity in response to either the 60% or 80% treatment 
sessions. This data indicates that a change in ox-LDL was not associated with a change in 
PON1 activity following the exercise treatments.  
 
 
 
  
Figure 8. Correlation between Ox-LDL and PON1 
Changes, 60% PRE-0 POST 
 
 
Figure 10. Correlation between Ox-LDL and PON1 
Changes, 80% PRE-0 POST 
 
Figure 9. Correlation between Ox-LDL and PON1 
Changes, 60% PRE-15 POST 
 
 
Figure 11. Correlation between Ox-LDL and PON1 
Changes, 80% PRE-15 POST 
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Effect of Ventilatory Threshold 
 Performance during the 80% exercise treatment was stratified based on intensity 
above or below ventilatory threshold (VT). Eleven of the 15 subjects ran above their 
ventilatory threshold during the 80% treatment. Further analyses were performed on these 
11 subjects to assess if VT moderated the variables of ox-LDL concentration, PON1 
activity, PC and TAC. ANOVA revealed no significant changes in ox-LDL or PON1 
across the time points PRE, 0 POST and 15 POST. Repeated measures t-tests found no 
significant changes in PC or TAC from PRE to 0 POST. In addition, it was speculated 
that magnitude of exercise intensity above VT could have an effect on the response of ox-
LDL, PON1, PC and TAC. However, Pearson product moment correlations revealed no 
significant relationships between percent of VO2 above VT and changes in ox-LDL 
concentration or PON1 activity from PRE to 15 POST or from PRE to 0 POST. 
According to these analyses, exercise intensity in relation to VT had no significant effect 
on the exercise-induced response of ox-LDL concentration, PON1 activity, PC or TAC.  
 
Effect of Baseline Low-Density Lipoprotein and High-Density Lipoprotein 
 Pearson product moment correlations were used to assess the relationship between 
baseline LDL and HDL concentrations and changes in ox-LDL concentration and PON1 
activity, respectively. No significant association was found between baseline LDL and 
changes in ox-LDL at 0 POST (60%, r = 0.256, p = 0.356; 80%, r = -0.377, p = 0.166) or 
at 15 POST (60%, r = 0.446, p = 0.096; 80%, r = 0.082, p = 0.773). Similarly, no 
significant relationship was found between baseline HDL and changes in PON1 activity 
at 0 POST (60%, r = 0.078, p = 0.783; 80%, r = -0.051, p = 0.858) or at 15 POST (60%, r 
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= 0.079, p = 0.778; 80%, r = -0.313, p = 0.256). Therefore, it appears that changes in ox-
LDL concentration and PON1 activity were not affected by baseline concentrations of 
LDL and HDL, respectively.  
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CHAPTER V 
DISCUSSION 
 
 The primary objective of this investigation was to examine the relationship 
between ox-LDL and PON1. To meet this objective, an acute exercise model was 
employed which was designed to perturb the basal homeostasis of oxidative stress, and 
thus ox-LDL concentration and PON1 activity. The observation of ox-LDL and PON1 in 
response to the exercise stimulus was intended to provide a new understanding of their 
association in vivo. To gain further knowledge of this relationship, two exercise bouts 
differing in intensity were utilized; each anticipated to produce different levels of 
oxidative stress.  
 Treadmill running at 60% and 80% maximal capacity for 30 minutes was chosen 
as the exercise protocol. Previous research has demonstrated that exercise between 70-
80% VO2 max is sufficient to generate elevated oxidative stress (Bryant, Ryder, Martino, 
Kim, & Craig, 2003; Goldfarb, McKenzie, & Bloomer, 2007; Goldfarb, et al., 2005). 
Therefore, the 80% treatment session was hypothesized to be an adequate stimulator of 
oxidative stress. Since the oxidative stress response to acute exercise has been shown to 
be intensity dependent (Goto, et al., 2007), the two exercise treatments were hypothesized 
to produce significantly different levels of oxidative stress.  
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 Physically active individuals who participated in at least 90 minutes of exercise 
per week at an intensity of 6 or above on the 10 point Borg scale (Borg, 1998) for the 
previous 3 months were eligible to participate. Trained individuals were recruited based 
on the results of a previous study. Tomas et al. (2002) measured ox-LDL concentration 
and PON1 activity following acute exercise before and after 16 weeks of training. 
Following the initial acute exercise session, no change in ox-LDL concentration and 
PON1 activity was detected. However, after 16 weeks of exercise training the acute 
session was repeated with significant increases in ox-LDL concentration and PON1 
activity immediately following exercise. Based on the evidence that trained subjects 
showed a significant change in PON1 activity in response to acute exercise but untrained 
subjects did not, trained subjects were recruited to participate in the current investigation.  
 Previous acute-model, oxidative stress studies have found significant results 
utilizing relatively small sample sizes. Tomas et al. (2002) recruited 17 subjects, 
Wetzstein et al. (1998) utilized 23 participants, while Goldfarb et al. (2005) and Bryant et 
al. (2003) examined 12 and 7 subjects, respectively. In the current study, a moderate 
effect of the treatment was anticipated, therefore and effect size of 0.5 was entered into 
G*Power (Franz Faul, Universität Kiel, Germany) which calculated that a total sample 
size of 14 subjects would be required. As a precaution, one additional subject was 
recruited making the total 15 subjects. In light of the previous investigations, this seemed 
to be a reasonable subject size to successfully power the investigation.
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Male and Female Participants 
Men and women were allowed to participate in this study. With that, one could 
speculate that hormonal difference may have compromised the results. However, 
previous research supports the contention that sex should not affect the outcome of this 
investigation. Exercise-related studies have utilized males and females when measuring 
ox-LDL and PON1 (Iborra, et al., 2008; Tomas, et al., 2002). Although sex differences in 
PON1 activity have been reported in inbred strains of mice, bin Ali et al. (2003) asserted 
that the genetic heterogeneity in humans should result in no sex effects in PON1 activity. 
Furthermore, in a human study Mueller et al. (1983) found no significant difference in 
serum PON1 activity between 113 males and 89 females. Also, menstrual cycle phase 
does not affect LDL oxidizability (Ruiz-Sanz, et al., 2007).  Twenty-eight premenopausal 
women had blood drawn on days 3 (menstrual phase), 14 (follicular phase), and 22 (luteal 
phase). In vitro LDL oxidation, particle size, fatty acid composition, and alpha-
tocopherol content were measured. The authors found no difference in oxidized LDL lag 
time, LDL diameter, alpha-tocopherol content, or fatty acid composition across the time 
points. They concluded that the menstrual cycle had no significant effect on LDL 
physiochemical properties or oxidizability. In addition Chung, Goldfarb, Jamurtas, and 
Lee (1999) found that menstrual cycle had minimal influence on oxidative stress markers 
in response to 30 minutes of exercise at 75-80% VO2max. In the current study the effects 
of gender were assessed through separate analyses of the males and females. No 
significant results were found when analyzing males only, females only, and comparing 
males to females.
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Ox-LDL Response to Exercise 
 The present study revealed no significant change in ox-LDL concentration in 
response to 30 minutes of aerobic treadmill exercise at 60% and 80% VO2 max. Therefore, 
the data do not support the hypothesis that ox-LDL concentration will increase in 
response to acute exercise to a greater extent with the higher exercise intensity. 
 Other investigations in which subjects were required to exercise for a moderate 
duration at a moderate to vigorous intensity have reported no change in ox-LDL or 
oxidized lipid markers following a single exercise session (Iborra, et al., 2008; 
Klapcinska, et al., 2005; Tozzi-Ciancarelli, et al., 2002). However other studies have 
reported elevations (Tomas, et al., 2002; Wetzstein, et al., 1998). Several issues are likely 
to be responsible for the disagreement amongst these and the current investigation. The 
most prominent of these issues are training status, exercise protocol and lipid oxidation 
marker. 
 Klapcinska et al. (2005) recruited young, fit soccer players and found an increase 
in ox-LDL antibodies following acute exercise. Not only was the ox-LDL marker 
different from the current investigation, but the exercise protocol involved progressive 
intense exercise bouts with short rest periods. Tozzi-Ciancarelli et al. (2002) found no 
change in LDL susceptibility to in vitro oxidation. However, subjects exercised at 60% 
VO2 max, an intensity that most likely was not sufficient to induce changes in ox-LDL. 
Iborra et al. (2008) reported no change in ox-LDL concentration following 40 minutes of 
cycle ergometry at 70-80% VO2 peak in type 2 diabetes mellitus patients and controls. 
This study measured ox-LDL concentration with an ELISA technique (identical to the 
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current study) but measurements were taken 40 minutes after exercise and not 
immediately post, making the results difficult to compare. 
 Two previous studies have interesting comparisons to this dissertation. One study 
examined the time to in vitro oxidation of isolated LDL particles. This metric, although 
different than the one used in this dissertation, provides an indication of the susceptibility 
of LDL to oxidation. Wetzstein et al. (1998) found an increase in vulnerability of LDL to 
in vitro oxidation immediately following 30 minutes of treadmill exercise at 55% 
(untrained) and 70% (trained) VO2peak. This effect was found in the total group (n=23), 
however when the trained (n=11) and untrained (n=12) were analyzed separately no 
significant increase was detected. Although possibly a sample size issue, the lack of 
increase in the lipid oxidation marker in the trained group is in agreement with the 
current study. In another investigation, Tomas et al.(2002) measured ox-LDL 
concentration (identical measurement as the current study) in response to 30 minutes of 
cycle ergometry at ventilatory threshold in individuals who had undergone 16 weeks of 
exercise training. They found a significant increase in ox-LDL concentration 
immediately, 1 hour, and 2 hours after the acute exercise session. This finding appears to 
be in contrast to this dissertation. However when closer comparisons are made between 
the fitness levels between Wetzstein et al., Tomas et al., and the current study, a 
noteworthy phenomenon appears. Wetzstein et al. utilized trained individuals (mean VO2 
max of 59.6 ml⋅kg-1⋅min-1) and found no change in LDL susceptibility to oxidation. This 
dissertation utilized trained individuals with a mean VO2 max of 54.8 ml⋅kg-1⋅min-1 and 
found no change in ox-LDL concentration. Tomas et al. utilized trained individuals with
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a mean VO2 max of 46.2 ml⋅kg-1⋅min-1 and found a significant increase in ox-LDL 
concentration. Despite similar ox-LDL concentrations before exercise (41.1 U/L, Tomas, 
et al.; 39.4 U/L, current study), in the Tomas et al. study ox-LDL concentration increased 
approximately 8 U/L in response to exercise while, in the current study, ox-LDL 
increased approximately 2.5 U/L in response to the 80% treatment. The fitness level of 
the participants could have had an effect on the ox-LDL response to an isolated exercise 
bout. Perhaps individuals who are highly exercise trained have LDL particles that are 
more resistant to oxidative stress. This concept is consistent with epidemiological data 
that have found an inverse dose-response relationship between fitness and CVD mortality 
(Blair, et al., 1989).  
 
PON1 Response to Exercise 
 This investigation detected no significant change in PON1 activity in response to 
30 minutes of exercise at 60% and 80% VO2 max. Therefore, the data do not support the 
hypothesis thatPON1 activity will increase in response to acute exercise to a greater 
extent with the higher exercise intensity. 
 It appears that sufficient oxidative stress must be present in order for significant 
changes in PON1 activity can be detected, but this observation is not consistent across all 
studies. Acute exercise investigations that produced significant oxidative stress have 
reported mixed results. Tomas et al. (2002) found that PON1 activity increased with ox-
LDL concentration immediately after exercise but then PON1 activity decreased 
significantly as ox-LDL remained elevated 1 and 2 hours post exercise. Tsakiris et al. 
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(2009) found a decrease in PON1 activity immediately after basketball practice with a 
concurrent decrease in total antioxidant status (an indication of oxidative stress). Thus, it 
appears that oxidative stress has an effect on PON1 activity, but the nature of this effect 
is not entirely clear. One study contrasts this, as thiobarbituric acid reactive 
substances(TBARS) were unchanged, yet PON1 activity increased following maximal 
exercise (Otocka-Kmiecik, et al., 2010). Several oxidative stress markers failed to reach 
significance in acute exercise studies that also found no change in PON1 activity post 
exercise (Benitez, et al., 2002; Hamurcu, et al., 2010; Iborra, et al., 2008). These findings 
are in line with the current study as PON1 activity was not significantly altered, along 
with oxidative stress markers (ox-LDL, PC, and TAC).  
 It was hypothesized in the current study that PON1 bioavailability would increase 
during an intense exercise bout as a mechanism to reduce exercise-induced oxidative 
stress, particularly the oxidative modification of LDL. However, likely due to the lack of 
change in the oxidative stress markers, this study provided no further insight to the PON1 
activity response to an isolated exercise bout.  
 Through personal communication with other researchers, it is believed that the 
particular PC kit used in this and other studies does not provide valid results. The 
concentrations have been found to be unexpectedly low on several accounts.  
 
Up-regulation of Antioxidant Protection through Chronic Exercise 
 Normal human serum total antioxidant capacity (TAC) contains a range of 0.5-2.0 
mM of Trolox equivalents (Koracevic, Koracevic, Djordjevic, Andrejevic, & Cosic, 
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2001; Miller, Johnston, Collis, & Rice-Evans, 1997). Participants in this investigation had 
a mean TAC value before exercise of 1.7 mM of Trolox equivalents, a value that is near 
the upper end of the normal range. The high TAC could have protected the subjects from 
oxidative changes during the exercise treatments. Furthermore, TAC remained high in 
response to the exercise sessions. The high level of antioxidant capacity may be an effect 
of the habitual exercise habits of the participants.  
 Exercise adaptations involving the up-regulation of endogenous antioxidants are 
suspected to have caused high TAC and prevented oxidative stress during the 80% 
exercise treatment. Exercise of sufficient duration and intensity in an isolated situation 
has the capacity to produce reactive oxygen species (ROS) and thus, oxidative stress. The 
primary sources of ROS during exercise are typically from the mitochondria respiratory 
chain, xanthine oxidase, NADPH oxidase, and myeloperoxidase (MPO) (Bejma & Ji, 
1999; Vina, et al., 2000). Increased oxygen flux during aerobic exercise can result in 
increased ROS generation in the mitochondria of the working muscle cells. Xanthine 
oxidase can product ROS when it reacts with oxygen and xanthine, a product of ATP 
degradation. NADPH oxidase and MPO produce ROS products through the activation of 
neutrophils during exercise. Because the presence of ROS is deleterious to cellular health, 
it has long been thought that oxidative stress is a negative consequence of physical 
exercise. However, now it is thought that the presence of oxidative stress is required for 
certain positive adaptations associated with physical activity. Indeed, oxidative stress can 
be viewed as having hormetic effects on the body, which is a particular dose-response 
relationship signifying  that exposure in low doses results in positive reactions while high 
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doses results in negative reactions (Ji, Gomez-Cabrera, & Vina, 2006; Radak, Chung, 
Koltai, Taylor, & Goto, 2008). Specifically, chronic exposure to low doses of oxidative 
stress, as with exercise, can result in up-regulation of antioxidant defenses, ultimately 
resulting in a stronger antioxidant capacity of the host (Gomez-Cabrera, et al., 2008; 
Radak, Chung, & Goto, 2008).   
 Several cell signal pathways are sensitive to the presence of antioxidant and pro-
oxidant substances. Hence, these cells are capable of adaptations specific to the 
reduction-oxidation (redox) environment to which they are subjected. One primary redox 
sensitive pathway of skeletal muscle involves the transcription factor nuclear factor κB 
(NF-κB) (Baeuerle & Baltimore, 1988).Upon activation by ROS, NF-κB has 
demonstrated the capacity to up-regulate gene expression of important antioxidants such 
as manganese superoxide dismutase (Mn-SOD), glutathione (GSH),and glutathione 
peroxidase (GPX) (Salminen & Vihko, 1983; Zhou, Johnson, & Rando, 2001). Mn-SOD 
is primarily found within the mitochondrial matrix and is the first line of defense against 
the mitochondrial production of ROS. Animal studies have shown that acute exercise 
resulted in NF-κB activation, and a subsequent increase in Mn-SOD mRNA (Gomez-
Cabrera, et al., 2005; Hollander, et al., 2001). GSH and GPX are considered independent 
antioxidants, yet they dependent on each other to carry out their antioxidant functions. 
GPX catalyzes the reaction between GSH and ROS, reducing the ROS. Sekhar et al. 
(1997) demonstrated that the production of γ-glutamylcysteinesynthetase(GCS), the rate 
limiting enzyme for GSH production, is dependent on the NF-κB pathway.  In addition, 
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oxidative stress has demonstrated the capacity to induce GPX mRNA expression via NF-
κB in a mouse skeletal muscle cell culture (Zhou, et al., 2001). Furthermore, exercise 
training studies have found increased enzymatic activity of Mn-SOD and GPX (Roberto 
Elosua, et al., 2003; Higuchi, Cartier, Chen, & Holloszy, 1985; Hollander, et al., 1999; 
Leeuwenburgh, Fiebig, Chandwaney, & Ji, 1994; Miyazaki, et al., 2001; Powers, et al., 
1994) and enhanced GSH content (Leeuwenburgh, et al., 1994; Leeuwenburgh, et al., 
1997; Marin, Kretzschmar, Arokoski, Hanninen, & Klinger, 1993; Sen, Marin, 
Kretzschmar, & Hanninen, 1992). Thus, it appears ROS produced during exercise can act 
as cell signaling agents to enhance the antioxidant system.  
 The lack of significant change in ox-LDL, PC and TAC in the current study was 
most likely due to the high training status of the participants, which provided them with 
high antioxidant capability. A chronic stressor such as exercise can make the body more 
resilient to future exercise-induced oxidative stress episodes. The regular activation of the 
NF-κB pathway in all likelihood resulted in advanced endogenous enzymatic antioxidant 
capacity, particularly Mn-SOD, GPX and GSH. It seems that chronic adaptations allowed 
the participants to perform the more intense exercise treatment rather easily; as the 
average RPE was 14.1, which was below 15, or a category of “hard.” Thus, an exercise 
bout of 80% VO2 max for 30 minutes could have been well within their antioxidant 
capabilities and no significant oxidative stress was observable.  
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Effects of Exercise above Ventilatory Threshold  
 Further evidence of highly developed ROS reducing capability was shown 
through the lack of evidence of oxidative stress in the subjects who exercised above 
ventilatory threshold (VT) (n=11). VT is the point at which minute ventilation increases 
disproportionately to oxygen consumption, and physiologically represents high aerobic 
energy production and increased reliance on anaerobic metabolism. The high aerobic 
turnout of supra-VT exercise was expected to elicit elevated ROS. However, it seems that 
the antioxidant ability of the participants was able to maintain homeostasis. Still this 
phenomenon should be interpreted with caution. When analyzing this cohort of 11 
subjects the ability to reach statistical significance with this small sample size must be 
taken into consideration. 
 
Relationship between Ox-LDL Concentration and PON1 Activity  
 No significant correlation was found at any time point between the changes in 
PON1 activity and ox-LDL concentration in response to the 60% and 80% exercise 
treatment sessions. Therefore, the data do not support the hypothesis that a significant 
correlation will exist between exercise-induced changes in ox-LDL concentration and 
PON1 activity in response to the relatively low exercise treatment. In addition the data do 
not support the hypothesis that a significant correlation will exist between exercise-
induced changes in ox-LDL concentration and PON1 activity in response to the relatively 
high exercise treatment is also rejected. 
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 The changes in ox-LDL concentration and PON1 activity are remarkably flat 
from PRE to 0 POST, however trends appear in both variables at 15 POST. Ox-LDL 
concentration average displayed a nonsignificant increase at 15 POST while PON1 
activity average showed a nonsignificant decrease. These trends are slightly more 
prominent following the 80% treatment. This small divergence in ox-LDL concentration 
and PON1 activity could possibly be due to the interaction between the PON1 enzyme 
and the ox-LDL particles. PON1 activity has been shown to decrease upon hydrolysis of 
an oxidized lipid target (Aviram, et al., 1999). This phenomenon has also been attributed 
to the observed decrease in PON1 activity by Tomas et al. (2002) and Tsakiris et al. 
(2009). In the current study, the concept of an interaction between ox-LDL and PON1 
and their subsequent changes is merely speculative. Unfortunately, the treatment sessions 
within this dissertation were insufficient to induce significant changes in ox-LDL 
andPON1. Therefore a conclusion concerning the in vivo relationship between ox-LDL 
and PON1 is difficult to produce.  
 When assessing the relationship between ox-LDL and PON1 in vivo one must 
take into consideration the method in which PON1 enzymatic activity is measured. As 
mentioned in Review of Literature, PON1 is considered a promiscuous enzyme due to its 
activity toward several substrates. At this time the only substrates for analyzing PON1 
activity are substances not naturally found in the human body (paraoxon, phenylacetate, 
diazoxon, etc). The natural substrate for PON1 appears to be oxidized lipids. However 
this substrate is not used to measure PON1 activity. Research has shown that the PON1 
enzyme has different methods of hydrolysis to different substrates. Aviram et al.(1998) 
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found that a sulfhyrdyl group was necessary for PON1 to hydrolyze oxidized lipids, but it 
was not required to hydrolyze paraoxon or phenylacetate. In addition, a calcium binding 
site seems to be very important. The chelating agent ethylenediaminetetraacetic acid 
(EDTA) removed calcium ions from PON1 and rendered the enzyme irreversibly inactive 
to phenylacetate (Kuo & La Du, 1998). However, calcium binding is not required for 
PON1 to protect LDL from oxidation (Aviram, Billecke, Sorenson, et al., 1998). In the 
current study, PON1 activity was measured in serum with no EDTA agent to retain the 
enzyme’s calcium component. Phenylacetate was used as a substrate, so the above 
statements apply here; this is not the most accurate method of measuring PON1 activity 
in vivo. An oxidized lipid substrate would provide the best information regarding changes 
in PON1’s ability to protect LDL from oxidation. This would also most likely be a more 
precise marker in identifying the changes in PON1 activity in relation to ox-LDL. It is 
possible that a change in the affinity for oxidized lipids does not mirror the change in the 
affinity for other substrates, like paraoxon or phenylacetate. Therefore a change in the 
activity toward one substrate could be altered by exercise while the activity toward 
another substrate reacts differently. Currently paraoxon and phenylacetate appear to be 
equally effective at identifying changes in PON1 activity in response to exercise, but an 
oxidized lipid substrate or similar substance may be needed for more accurate 
assessment. Future research should aim to produce an oxidized lipid-based substrate 
technique for the assessment of PON1 activity. Then, the nature of the in vivo 
relationship between ox-LDL concentration and PON1 activity can be more accurately 
assessed.  
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 As stated in Review of Literature, the primary location of LDL oxidation is 
thought to be within the subendothelial space, not within the circulation. HDL can also 
traverse the endothelial layer where it can participate in reverse cholesterol transport by 
removing cholesterol from macrophages. Therefore it is believed, but not yet 
demonstrated, that PON1 can disrupt ox-LDL formation in the subendothelium. This is 
the most likely location where PON1 has the greatest capacity to act as a cardioprotective 
enzyme. However, this study measured the concentration of ox-LDL and activity of 
PON1 in the circulation. A more accurate and meaningful measurement of the in vivo 
relationship between ox-LDL and PON1 should be done in the vascular tissue. Their 
relationship is assumed to be very similar in the vascular tissue and the circulation, but 
this is not known. In addition, the effects of exercise may be different between the artery 
wall and the circulation. Future investigations should attempt to measure the in vivo 
dynamics of ox-LDL and PON1 in the arterial wall in animal models.  
 
Conclusions 
 The antioxidant PON1 enzyme has demonstrated important cardioprotective 
characteristics in epidemiological and in vitro investigations. For these reasons, a greater 
understanding of how PON1 protects the vasculature could be very important. However, 
information regarding the nature of PON1 in vivo is lacking. This study attempted to 
ascertain new information concerning the relationship between ox-LDL and PON1. 
Utilizing an acute exercise model, ox-LDL concentration and PON1 activity were 
expected to change proportionately in response to acute exercise, signifying a biological 
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connection. However, no significant changes in ox-LDL concentration or PON1 activity 
were observed immediately and 15 minutes after treadmill running at 60% and 80% VO2 
max. In addition, no significant correlations were measured between the changes in ox-
LDL concentration and PON1 activity in response to acute exercise. Therefore, in this 
exercise model there was no relationship between ox-LDL and PON1. Oxidative stress in 
this cohort was apparently not induced through the exercise sessions, presumably due to 
the high training status and, as such, high antioxidant capability of the subjects. It is 
recommended that future investigations utilizing exercise to measure ox-LDL and PON1 
recruit individuals who are not highly trained. It is still plausible that PON1 activity 
responds to a change in ox-LDL concentration, and more investigations are needed to 
elucidate the nature of this relationship.  
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APPENDIX A 
RECRUITMENT FLYER 
Test Your Fitness! 
Participants are needed for a research study investigating the effect of different exercise 
intensities on various cardiovascular disease risk markers. Maximal oxygen consumption 
(VO2 max), body fat percentage, and cholesterol levels will also be assessed; an 
approximate $200 value for free! 
You may be eligible for this study if you: 
 
You are not eligible for the study if you: 
• Are between the ages of 18-35 
• Exercise at least 90 minutes per 
week at a moderate to vigorous 
intensity 
• Have abnormally high blood 
pressure (≥140 mm Hg systolic or 
≥90 mm Hg diastolic) 
• Meet the study’s height/weight 
criteria (please call or e-mail to find 
out if you meet this requirement) 
• Use tobacco products or illegal 
drugs 
• Drink more than an average of 2 
alcoholic drinks per day 
• Have diabetes or any disease 
affecting the heart, kidneys, or any 
other major organ 
 • Are, or think you might be, 
pregnant 
• Currently use vitamin/mineral 
supplementation or hormonal birth 
control 
 
Volunteers meeting the study requirements will exercise on three separate occasions in 
the exercise physiology laboratory.  The study will last approximately two weeks.  Body 
fat percentage, cholesterol levels, blood pressure, and VO2 max will be measured 
throughout the study.  
 
For more information please contact: Charlie Robison, M.S., Kinesiology Department, 
UNCG 
573-718-7661 (cell) or cerobiso@uncg.edu 
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APPENDIX B 
 
HEALTH HISTORY QUESTIONNAIRE 
 
Health History Questionnaire 
All of the information below is necessary to 1) insure your safety as a participant in this 
study, 2) to determine if you meet the qualification guidelines of this study, and/or 3) for 
the reporting of the demographics of this study.  Please answer all questions accurately.  
If you are unsure as to how to answer any question, please notify the investigator.  All 
information on this form will be kept confidential. 
 
Name ______________________________________ 
 
Age __________   Birth date______________________ 
 
Emergency contact:   Name ______________________________________   
 
Phone #_________________ 
 
Please check the appropriate responses: 
1. What is your ethnicity/race (check all that apply)? 
 
_____African American   _____White   _____Asian     
 
_____Latino _____Other (please list)____________________ 
 
2. Do you use tobacco products? 
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_____Yes   _____No 
3. If you answered “no” to Question #2, have you ever used tobacco products on a 
regular basis in the past? 
 
_____Yes   _____No 
 
4. If you answered “yes” to Question #3, how long ago did you quit? 
_______________________________ 
 
5.  Do you regularly consume more than two alcoholic drinks per day? 
 
_____Yes   _____No 
 
6. Have you ever been told that you have high blood pressure? 
 
_____Yes   _____No 
 
To your best knowledge, what is your blood pressure?_______________________ 
 
7.  Do you know your: 
 
  A)  cholesterol level?  _____Yes  _____No  If yes, what is it?________ 
  B)  LDL-cholesterol level?  _____Yes  _____No If yes, what is it?________ 
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  C)  HDL-cholesterol level?  _____Yes  _____No If yes, what is it?________ 
 
8. Have you ever been told by a doctor that you should not exercise or that you should 
only exercise under medical supervision? 
 
_____Yes   _____No 
 
9. Have you ever had problems with chest discomfort or dizziness? 
 
_____Yes   _____No  
 
10. Have you ever had a stroke or heart attack? 
 
_____Yes   _____No 
 
11. Are you diabetic? 
 
_____Yes   _____No 
 
12. Are you, or do you think that you may be, pregnant? 
 
 _____Yes   _____No 
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13. Do you have any bleeding disorders? 
 
_____Yes  _____No 
14. How many days per week do you exercise? 
 
 
15. In what type(s) of exercise do you participate? 
 
 
 
 
 
 
16. What is the average amount of time you spend participating in each activity? 
 
 
 
 
 
 
17. Do your answers to Questions 12-15 represent your exercise habits for at least the 
past three months? 
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_____Yes   _____No 
 
 
18.  Please list all prescribed and/or over-the-counter medications (including birth 
control), nutritional supplements, and vitamins that you take on a regular basis. 
 
 
 
 
I have answered all the above questions truthfully to the best of my ability. 
 
Signature of participant_________________________________________________ 
 
Date________________________________ 
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APPENDIX C 
 
PHYSICAL ACTIVITY QUESTIONNAIRE 
 
1.  For the last twelve months, which of the following moderate or vigorous activities  
have you performed regularly?  (Please circle YES for all that apply and NO if you  
do not perform the activity; provide an estimate of the amount of activity for all  
marked YES.  Be as complete as possible). 
 
Walking 
NO YES  → How many sessions per week?  ________ 
   How many miles (or fractions) per session? ________ 
   Average duration per session?  ________ (minutes) 
 
 What is your usual pace of walking?  (Please circle one) 
 
 CASUAL or  AVERAGE or  FAIRLY          BRISK or 
 STROLLING  NORMAL  BRISK          STRIDING 
 (< 2 mph)  (2 to 3 mph)  (3 to 4 mph)          (4 mph or faster) 
 
Stair Climbing 
NO YES → How many flights of stairs do you climb UP each day? _________ 
   (1 flight = 10 steps) 
 
Jogging or Running 
NO YES → How many sessions per week?  ________ 
   How many miles (or fractions) per session? ________ 
   Average duration per session?  ________ (minutes) 
 
Treadmill 
NO YES → How many sessions per week?  ________ 
   How many miles (or fractions) per session? ________ (minutes) 
   Speed?_____ (mph) Grade? _____ (%) 
 
Bicycling 
NO YES → How many sessions per week?  ________ 
   How many miles per session?  ________ 
   Average duration per session?  ________ (minutes) 
 
Swimming Laps  → How many sessions per week?  ________ 
NO YES  How many miles per session? 
     (880 yds = 0.5 miles)   ________ 
   Average duration per session?  ________ (minutes) 
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Aerobic Dance/Calisthenics/Floor Exercise 
NO YES → How many sessions per week?  ________ 
   Average duration per session?  ________ (minutes) 
 
Moderate Sports 
(e.g. Leisure volleyball, golf (not riding), social dancing, doubles tennis) 
NO YES → How many sessions per week?  ________ 
   Average duration per session?  ________ (minutes) 
 
 
Vigorous Racquet Sports 
(e.g. Racquetball, singles tennis) 
NO YES → How many sessions per week?  ________ 
   Average duration per session?  ________ (minutes) 
 
Other Vigorous Sports or Exercise Involving Running 
(e.g., Basketball, soccer) 
NO YES → Please specify:________________________________ 
   How many sessions per week?  ________ 
   Average duration per session?  ________ (minutes) 
 
Other Activities 
NO YES → Please specify:________________________________ 
   How many sessions per week?  ________ 
   Average duration per session?  ________ (minutes) 
 
Weight Training 
(Machines, free weights) 
NO YES → How many sessions per week?  ________ 
   Average duration per session?  ________ (minutes) 
 
Household Activities (i.e., Sweeping, vacuuming, washing clothes, scrubbing floors) 
NO YES → How many hours per week?   ________ 
 
Lawn Work and Gardening 
NO YES → How many hours per week?   ________ 
 
 
2.  How many times a week do you engage in vigorous physical activity long enough to  
work up a sweat? ________ (times per week) 
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APPENDIX D 
 
INFORMED CONSENT FORM 
 
UNIVERSITY OF NORTH CAROLINA AT GREENSBORO 
CONSENT TO ACT AS A HUMAN PARTICIPANT: LONG FORM 
 
Project Title:  The relationship between oxidized low-density lipoprotein and 
paraoxonase 1 following acute exercise 
 
Project Director:  Paul G. Davis, Ph.D. 
 
Participant's Name:        
 
What is the study about?  
This is a research project.The purpose of this study is tomeasure the relationship between 
two substances found in the blood (oxidized low-density lipoprotein and paraoxonase-1) 
in response to exercise sessions of differing intensities.  These substances are very 
important in the development of cardiovascular disease. Information obtained from this 
study will provide new information concerning the function of paraoxanase-1, a 
beneficial substance against atherosclerosis development. 
 
Why are you asking me? 
Individuals within the age of 18-35 years and who have performed vigorous aerobic 
exercise (running, cycling, etc.) for at least 90 minutes per week for the past 3 months are 
eligible to participate in this study.  Reasons that you may not participate in this 
investigation include history of cardiovascular disease, diabetes mellitus, dyslipidemia, 
physical disability, and chronic respiratory disease. Other exclusion criteria include 
individuals with a body mass index (BMI) ≥25 kg/m2, resting blood pressure ≥140 mm 
Hg (systolic) or ≥90 mm Hg (diastolic), regular consumption of >2 alcoholic drinks per 
day, tobacco use, oral birth control use and regular vitamin or mineral supplementation 
within the past 2 months.  
 
What will you ask me to do if I agree to be in the study? 
In this study, you will be asked to visit the laboratory on three different occasions:  to 
participate in a fitness assessment test and to complete two different exercise treatments.  
The fitness assessment test will be used to determine your maximal oxygen consumption 
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(VO2 max), a measure of cardiorespiratory fitness. This test last approximately 12 minutes 
and will start at a slow jogging speed and progress in intensity to where you are running 
up a steep incline. It is important for you to give a maximal effort during this test.  
However, if you feel anything unusual at any time, you should inform the researcher 
immediately and, if necessary, the test will be terminated.  You also have the right to 
terminate any procedure of this experiment at any time. In the two subsequent exercise 
treatments, you will be asked to exercise on a treadmill for 30 minutes at 60% (moderate-
to-vigorous intensity) and 80% (very vigorous intensity) VO2 max. You will be asked to 
abstain from eating or drinking any food (except water) for 12 hours before two of the 
exercise sessions. Blood will be drawn by a trained technician immediately before, 
immediately after, and 15 minutes after these two exercise sessions. You will also be 
asked to record food intake and recall physical activity prior to two of the exercise 
sessions. The maximal exercise session will last approximately 45 minutes.  Exercise 
treatment sessions will last approximately 75 minutes.  The entire study lasts 
approximately 2 weeks. Participants may call or email Charles Robison (573-718-7661, 
cerobiso@uncg.edu) or Paul Davis (336-334-3030, pgdavis@uncg.edu) with any 
questions about these procedures.  
 
What are the dangers to me? 
Maximal exercise testing and moderate/high-intensity exercise carry a very remote 
chance of a heart attack or sudden death. Fit, young individuals (ages 18-35) rarely 
experience cardiac events. Research has found that exercise related death among young 
athletes is one per 133,000 men and 1 per 769,000 women, with the most common causes 
of death stemming from congenital or hereditary cardiac abnormalities.Safety shall be 
enhanced through use of trained personnel in blood collection procedures and 
administration of maximal graded exercise test. Standard emergency protocol will 
include, if needed, cardiopulmonary resuscitation (CPR), use of an automated external 
defibrillator, and notification of the Emergency Medical Service (EMS). In addition, 
there is a slight possibility that you will feel weak or faint from fasting. You should tell 
the experimenter immediately if you experience any unusual sensations before, during, or 
after exercise. Since you do not have known heart, lung, or metabolic disease, do not 
smoke, and do not have severely high blood pressure, the potential benefit of 
participation most likely outweighs the risk. In addition, a chance of bruising and a very 
slight chance of infection exists with blood collection. This will be minimized through 
use of a trained technician and sterile materials. Neither the investigator nor UNCG will 
be financially responsible for any compensation should you become injured during this 
study.If you have any concerns about your rights, how you are being treated or if you have 
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questions, want more information or have suggestions, please contact Eric Allen in the 
Office of Research Compliance at UNCG at (336) 256-1482.  Questions, concerns or 
complaints about this project or benefits or risks associated with being in this study can 
be answered by Paul G. Davis who may be contacted at 336-334-3030 or 
pgdavis@uncg.edu  
 
Are there any benefits to me for taking part in this research study? 
For no charge, you may receive information concerning your cardiorespiratory fitness 
(VO2max), body composition, blood pressure, and plasma lipid/lipoprotein profile.  
 
Are there any benefits to society as a result of me taking part in this research? 
Results from this study may provide new information regarding the protective effect of 
exercise against heart attack and stroke prevention, the number one and three causes of 
death to Americans.  
 
Will I get paid for being in the study?  Will it cost me anything? 
There are no costs to you or payments made for participating in this study. 
 
How will you keep my information confidential? 
All information obtained in this study is strictly confidential unless disclosure is required 
by law.  Subject data files are kept in a locked location and only anonymous data will be 
reported. Non-anonymous data will not be transferred via the internet or any other non-
secure source. Persons working on the proposed project will take or have taken IRB-
approved training on the proper handling of participant information.   
 
What if I want to leave the study? 
You have the right to refuse to participate or to withdraw at any time, without penalty.  If 
you do withdraw, it will not affect you in any way.  If you choose to withdraw, you may 
request that any of your data which has been collected be destroyed unless it is in a de-
identifiable state. 
 
What about new information/changes in the study?  
If significant new information relating to the study becomes available which may relate 
to your willingness to continue to participate, this information will be provided to you. 
 
Voluntary Consent by Participant: 
By signing this consent form you are agreeing that you read, or it has been read to you, 
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and you fully understand the contents of this document and are openly willing consent to 
take part in this study.  All of your questions concerning this study have been answered. 
By signing this form, you are agreeing that you are 18 years of age or older and are 
agreeing to participate, or have the individual specified above as a participant participate, 
in this study described to you by     .  
 
Signature: ________________________ Date: ________________ 
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APPENDIX E 
PRESCREENING DATA FORM 
Prescreening Data 
Subject number_________ 
Date__________________ 
Name________________________    Weight ________kg _______lbs 
Sex   M     F      Height ________cm _______ins 
Blood pressure      BMI _______kg/m2    
Right arm 
___________mm Hg      ___________mm Hg 
Left arm 
___________mm Hg      ___________mm Hg 
Resting HR ________ bpm   ________bpm    ________ bpm ________bpm 
Skinfolds 
      1st measurement   2nd measurement           3rd measurement                Average 
         (if needed) 
Pectoral    ________mm ________mm  ________mm  ________mm 
 
Subscapular ________mm ________mm  ________mm  ________mm 
 
Triceps  ________mm ________mm  ________mm  ________mm 
 
Midaxillary ________mm ________mm  ________mm  ________mm 
 
Suprailiac ________mm ________mm  ________mm  ________mm 
 
Abdominal ________mm ________mm  ________mm  ________mm 
 
Thigh  ________mm ________mm  ________mm  ________mm  
 
         Total=  ________mm 
 
                 % body fat = ________ % 
 
134 
 
APPENDIX F 
 
RATING OF PERCEIVED EXERTION SCALE 
 
     Category Scale      
 
6 
 
7  Very, Very Light 
 
8 
 
9  Very Light 
 
          10 
 
11 Fairly Light 
 
12 
 
13 Somewhat Hard 
 
14  
 
15 Hard 
 
16  
 
17 Very Hard 
 
18 
 
19  Very, Very Hard 
 
20  
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APPENDIX G 
 
VO2 MAX DATA FORM 
 
Name:___________________________               Age:_______     Subject #:________ 
 
Date:______________ 
 
Pre-exercise HR:________                 Pre-Exercise BP:__________ 
 
Age Predicted Max HR:_________  
  
Stage Stage 
Length 
HR RPE VO2 Comments 
1 
4.5 mph 
     
2 
4.8 mph 
     
3 
5.2  mph 
     
4 
5.6mph 
     
5 
6.0mph 
     
6 
6.3mph 
     
7 
6.7mph 
     
8 
7.1mph 
     
9 
7.4mph 
     
10 
7.8mph 
     
11 
8.2mph 
     
12 
8.6mph 
     
13 
8.9mph 
     
14 
9.3mph 
     
15      
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9.7mph 
16 
10.0mph 
     
17 
10.4mph 
     
18 
10.8mph 
     
 
Termination Time:__________         Immediate-post VO2:__________ 
 
Immediate-post HR:__________          Immediate-post BP:_______________ 
 
Reason for Termination:___________________________________________ 
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APPENDIX H 
 
FOOD DIARY DATA FORM 
 
 
Please list ALL food and drink consumed during the three days before each experimental 
session. Use a separate sheet for each day and refer to the following examples for ideas 
on how specific you should be. 
7:00am Eggs (fried) 2 whole (jumbo) 180 
    4 whites (jumbo) 75 
  wheat bread 3 slices 200 
  jelly (grape) 3 tsp. ? 
  orange juice (conc.) 2 cups 200 
11:00am Rice (instant/white) 1 cup (dry) 300 
  baked chicken 8 oz. 300 
  (boneless/white meat)    
  olive oil 2 tbs. 240 
 
Time Food Source Quantity (oz./cups) Calories (if known) 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
Name:     Day:     Date:    
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APPENDIX I 
 
SEVEN-DAY PHYSICAL ACTIVITY RECALL FORM 
 
 
Subject #________  Treatment (circle)  60%  80%  Date _______ 
 
INTENSITY CLASS 
0 = recreational 
exercise 
1=conditioning 
exercise 
2=brisk 
conditioning 
exercise 
3=competitive 
strenuous 
exercise 
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APPENDIX J 
EXERCISE TREATMENT DATA FORM 
 
Subject Name _________________  Treatment Session   60%____    80%____ 
Subject #____________ 
Subject fasted?  ______ 
No exercise/significant PA for 48 hrs? ______ 
Current Body Weight _______kg  ________lbs 
VO2 max _________ 
Target VO2 __________________ 
 
Timepoint (mins) RPE  VO2 (ml/kg-1/min-1) HR (bpm) 
 
5 
 
   
 
15 
 
   
 
25 
 
   
 
 
